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Abstract
Background: Aberrant patterns of DNA methylation are abundant in cancer, and epigenetic pathways are increasingly
being targeted in cancer drug treatment. Genetic components of the folate-mediated one-carbon metabolism pathway
can affect DNA methylation and other vital cell functions, including DNA synthesis, amino acid biosynthesis, and cell
growth.
Results: We used a bioinformatics tool, the Transcriptional Pharmacology Workbench, to analyze temporal changes in
gene expression among epigenetic regulators of DNA methylation and demethylation, and one-carbon metabolism
genes in response to cancer drug treatment. We analyzed gene expression information from the NCI-60 cancer cell line
panel after treatment with five antitumor agents, 5-azacytidine, doxorubicin, vorinostat, paclitaxel, and cisplatin. Each
antitumor agent elicited concerted changes in gene expression of multiple pathway components across the cell lines.
Expression changes of FOLR2, SMUG1, GART, GADD45A, MBD1, MTR, MTHFD1, and CTH were significantly correlated with
chemosensitivity to some of the agents. Among many genes with concerted expression response to individual antitumor
agents were genes encoding DNA methyltransferases DNMT1, DNMT3A, and DNMT3B, epigenetic and DNA repair factors
MGMT, GADD45A, and MBD1, and one-carbon metabolism pathway members MTHFD1, TYMS, DHFR, MTR, MAT2A, SLC19A1,
ATIC, and GART.
Conclusions: These transcriptional changes are likely to influence vital cellular functions of DNA methylation and
demethylation, cellular growth, DNA biosynthesis, and DNA repair, and some of them may contribute to cytotoxic
and apoptotic action of the drugs. This concerted molecular response was observed in a time-dependent manner,
which may provide future guidelines for temporal selection of genetic drug targets for combination drug therapy
treatment regimens.
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Background
Epigenetic dysregulation is common in cancer and it
involves, among other mechanisms, aberrant patterns of
gene-specific DNA methylation, DNA hydroxymethyla-
tion, and genome-wide hypomethylation [1]. Hypermethy-
lation of promoter regions of tumor suppressor genes in
malignant cells leads to their epigenetic silencing [1–4].
Abnormal DNA methylation patterns such as DNA hypo-
methylation also increase genome instability [2, 5].
Levels and locus-specific patterns of DNA methylation
are affected by a complex network of interactions among
molecular factors (Additional file 1: Table S1). They
include proteins directly involved in DNA methylation,
e.g., DNA 5′ cytosine-methyltransferases or DNMTs
(DNMT1, DNMT3A, and DNMT3B) and DNA hydro-
xymethylation and demethylation, such as ten-eleven
translocation methylcytosine dioxygenases (TET1, TET2,
and TET3), activation-induced cytidine deaminase (AICDA
or AID), apolipoprotein B mRNA editing activity DNA
deaminases (APOBEC1, APOBEC2, APOBEC3A, and
APOBEC3C), thymine-DNA glycosylase (TDG), and
demethylating DNA repair factors (O6-methylguanine-
DNA-methyltransferase, or MGMT, and growth arrest
and DNA damage 45 protein A, or GADD45A) [6–8].
Additional molecular factors include methyl-CpG-binding
domain proteins (MBDs), proliferating cell nuclear antigen
(PCNA), herpes virus-associated ubiquitin specific protease
USP7, single-strand-selective monofunctional uracil-DNA
glycosylase (SMUG1), and DNA methyltransferase 3-like
protein (DNMT3L) that act as interaction partners of pro-
teins involved in DNA methylation or demethylation, and
NADP+-dependent isocitrate dehydrogenases (IDH1 and
IDH2) that produce metabolites which interfere with TET-
mediated DNA demethylation [6, 9–13].
DNA methylation processes are also affected by reac-
tions in the folate-mediated one-carbon metabolism
(OCM) pathway. This pathway encompasses a complex
metabolic network of biosynthetic reactions in the cyto-
plasm, mitochondria, and the nucleus that involve S-ade-
nosylmethionine (SAM or AdoMet), homocysteine (Hcy),
folate, other B vitamins, and multiple cofactors [14–18].
The OCM pathway directly affects the activity of DNA
methyltransferases and other methylation processes in the
cell because reactions in that pathway involve the biosyn-
thesis of SAM, which serves as a donor of methyl groups
for DNA and other biological molecules. Furthermore,
transmethylation reactions that use SAM as a substrate
result in the conversion of SAM to S-adenosylhomocys-
teine (SAH), and SAH directly inhibits DNA methyltrans-
ferases [16, 17]. In addition to its influence on DNA
methylation, the OCM pathway is involved in other vital
cell functions that include purine and pyrimidine biosyn-
thesis, amino acid biosynthesis, and cell growth and prolif-
eration, all of which are highly important for rapidly
proliferating cancer cells [19]. The OCM pathway involves
multiple receptors, membrane transport proteins, and
numerous important regulatory enzymes that control its
reactions (Additional file 1: Table S1) [15, 17]. Genetic
variation and expression of the OCM genes and abnormal
levels of folate and Hcy have been associated with an in-
creased risk of cancer, changes in drug transport, response
to drug treatment, DNA methylation changes, DNA dam-
age, and genome instability [14–17, 20–26].
Molecular components involved in DNA methylation,
demethylation, and the OCM pathway have been targeted
in cancer treatment through the use of hypomethylating
agents (e.g., 5-azacytidine, or AZA, 2′-deoxy-5-azacitidine,
or decitabine, other DNA methyltransferase inhibitors,
and agents targeting other components of the methylation
machinery) and antifolate drugs (e.g., methotrexate, 5-
fluorouracil, aminopterin, pemetrexed, and other agents)
[1, 2, 14, 27–31]. Treatment of tumor cells with low
concentrations of 5-azacytidine results in global
epigenome-wide demethylation, which leads to tran-
scriptional reactivation of tumor suppressor genes that
had been silenced by methylation [2]. At high concen-
trations, treatment with 5-azacytidine results in direct
cytotoxicity rather than DNA hypomethylation [1].
Molecular mechanisms of action of 5-azacytidine
include its incorporation into RNA and DNA, trapping
of DNMT1, additional replication-independent mechanisms
of DNMT1 depletion, and inhibition of ribonucleotide
reductase, all of which leads to inhibition of transcription
and of protein metabolism, and to induction of apoptosis
[1, 2]. In the HCT-116 cancer cell line, 5-azacytidine
downregulates the expression of DNA methyltransferases
DNMT1 and DNMT3A [32].
In addition to hypomethylating agents such as 5-
azacytidine and decitabine, other cancer drugs with diverse
mechanisms of actions can downregulate DNA methyl-
transferases and affect methylation status of a variety of
genes. One of these agents is doxorubicin (Dox), an
anthracycline antibiotic that inhibits topoisomerase II,
generates reactive oxygen species (ROS), and causes
CRB3L1-mediated membrane proteolysis [33]. In the
HCT-116 cell line, doxorubicin downregulates the
expression of DNMT1 and diminishes its enzymatic
activity, leading to conditional apoptosis [34]. These
changes in transcription and activity of DNMT1 in re-
sponse to doxorubicin treatment did not lead to global
DNA hypomethylation in a cell line model [34], but in
live murine models, treatment with doxorubicin alone
or in combination with Pluronic block copolymers
resulted in the increase and decrease of methylation
levels of numerous promoters of biologically import-
ant genes [35].
A histone deacetylase (HDAC) inhibitor, vorinostat
(suberoylanilide hydroxamic acid, or SAHA) also affects
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DNA methylation. Treatment of tumor cells with vori-
nostat has been shown to downregulate transcription of
DNA methyltransferases DNMT1 and DNMT3b in the
A549 lung cancer line and to induce methylation changes
in important cancer-related genes such as human telomer-
ase reverse transcriptase (TERT, or hTERT) and “deleted
in liver cancer” (DLC1) [36–38].
DNA methylation and demethylation are not only
involved in the mechanism of action of some cancer
drugs but they have also been associated with sensitivity
to drug treatment. One example of such involvement is
MGMT, which participates in DNA repair by demethy-
lating O6-methylguanine lesions. It also removes larger
O6-alkyl adducts and is thereby involved in resistance to
nitrosourea-based anticancer drugs [39]. Hypermethyla-
tion of the MGMT promoter leads to transcriptional
repression of this gene, increasing cancer cell sensitivity
to chemotherapeutic agents and radiation [39–41].
Epigenetic mechanisms are also involved in resistance
to cisplatin, a small-molecule platinum compound that
interacts with DNA to form DNA adducts and activates
the apoptotic pathway [42]. Chemoresistance to cisplatin,
which can develop after an initial positive response to
treatment, has been associated with specific patterns of
DNA methylation and gene expression, along a complex
variety of other molecular changes [26, 41, 43–46].
Methylation of specific genes has been reported to
affect tumor cell sensitivity and resistance to pacli-
taxel (Taxol®), a widely used cancer drug that binds
to microtubules, disrupting their physiological as-
sembly and disassembly, and leading to cell cycle
arrest and apoptosis. At low concentrations, pacli-
taxel also has antiangiogenic properties and inhibits
tumor vasculogenesis [47, 48]. Resistance to pacli-
taxel and progression-free survival may be associated
with DNA methylation status of certain genes such
as SFN (stratifin) and CHFR (checkpoint with fork-
head and ring finger domains) [41, 49, 50].
Given the ubiquitous action of DNA methyltransferases
and other epigenetic factors that participate in methylation
and demethylation of DNA, and the link between DNA
methylation and the OCM pathway, it is important to
understand temporal patterns of the response of compo-
nents of these pathways to drug treatment. Such knowledge
is needed to gain an insight into molecular mechanisms of
drug sensitivity and acquired drug resistance, and to iden-
tify suitable molecular drug targets. To address these ques-
tions, we investigated time-dependent expression patterns
following treatment of cancer cell lines with several anti-
cancer drugs with diverse mechanisms of action. We
analyzed data from the NCI-60 cancer cell line panel, a well
characterized and widely used resource for cancer drug
screening and molecular biology studies of cancer [31, 51].
The time-course gene expression information was used to
examine the effects of five widely used drugs: 5-azacytidine,
vorinostat, doxorubicin, cisplatin, and paclitaxel, on the ex-
pression of multiple genes involved in DNA methylation,
demethylation, and one-carbon metabolism. Two of these
agents, 5-azacytidine and vorinostat, directly involve epi-
genetic mechanisms in their action, whereas doxorubicin
has been reported to affect the expression of DNA methyl-
transferases in addition to other modes of action. For cis-
platin and paclitaxel, epigenetic mechanisms involving
DNA methylation have been associated with resistance to
treatment. The goal of our analysis was to identify common
patterns of expression changes in DNA methylation,
demethylation, and OCM pathways among the different
cell lines in response to each of these agents. Such
common patterns may provide new knowledge about
molecular mechanisms of drug action and could suggest
potential novel gene targets for drug combination therapies.
We also examined whether changes in the expression of
these genes were associated with chemosensitivity to drug
treatment.
Results and discussion
The summary of gene expression changes in response to
treatment with five antitumor agents is presented in
Table 1. These results in Table 1 show concerted changes
in the expression of many important components of the
DNA methylation pathway, molecular factors involved in
DNA demethylation, and enzymes, receptors, and trans-
port proteins involved in the folate-mediated OCM path-
way. Many genes with biologically important roles had
concerted changes in expression, including multiple genes
with a very strong similar response across all cancer types
in the NCI-60 panel. In the majority of the experiments,
higher concentrations of antitumor agents resulted in con-
certed changes in the expression of a higher number of cell
lines and stronger amplitudes of expression changes than
did the lower concentrations of the same agents. The most
frequent time period when concerted changes were ob-
served across multiple cell lines was at 24 h after treatment
with cancer drugs. However, some individual genes had
more profound concerted changes at 2 or 6 h after treat-
ment (Table 1; Figs. 1 and 2; Additional file 2: Figures S2,
S7, S8, S10-S12, S14, S16, S17). The concerted changes in
expression were specific to individual agents, time points,
and treatment concentrations. As discussed below, these
concerted expression changes of epigenetic components
and OCM genes uniquely identify four of the agents, 5′
azacytidine, doxorubicin, vorinostat, and paclitaxel, or
similar agents from the same classes, in independent data-
sets of transcriptional response to drug treatment. These
changes identify elements of the DNA methylation, de-
methylation, and OCM pathways as differentially activated
and inactivated based on mechanism of action, but the
concerted nature of these responses indicate that they are
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Table 1 Summary of time-specific drug treatment effects on gene expression in the NCI-60 cell lines
Gene 5-Azacytidine Doxorubicin Vorinostat Paclitaxel Cisplatin
DNMT1 H↓24a; L↓24 H↓6, 24a HL↓2; H↓6a,24b; L↓6,24a H↓24 NC
DNMT3A NC NC H↓6a,24a; L↓6 NC NC
DNMT3B NC H↓6a, 24a H↑2a,6b; L↑2,6a NC NC
DNMT3L NC NC NC NC NC
TET3 H↑24a NC L↓6a; HL↓24a NC NC
AICDA NC NC NC NC NC
APOBEC1 NC NC NC NC NC
APOBEC2 NC NC NC NC NC
APOBEC3A NC NC NC NC NC
APOBEC3C H↓24a L↑24a H↓6a; HL↓24a NC H↑24a
TDG H↑6,24a NC H↓2,6,24a; ↓6,24 H↑24 H↑24
GADD45A H↑2b; HL↑6a,24b H↑24c; L↑24b H↑24b; L↑24a HL↑24b H↑6a,24bd; L↑24ad
IDH1 NC H↑2,6; L↓24b H↑2a,6a,24a; L↑2,6a,24a L↓6; HL↓24a H↓24a
IDH2 H↓24a H↑6,24a; L↑24 NC HL↓24 L↑24
MGMT H↓24a; L↓24 H↓24a NC NC H↓24b
MBD1 H↑24a; L↑24 H↑6,24a; L↑24 H↑6a,24a HL↑24 H↑24ad
MBD2 H↓24 HL↓24 H↓24 NC NC
MBD3 NC NC HL↓6a,24a NC NC
MBD4 H↓2aHL↑6 HL↑2; H↑6,24a HL↑2,6a NC H↑6,24a; L↑24
MeCP2 NC H↓6,24 HL↓6a; H↓24a; L↓24; NC NC
PCNA L↑6; HL↓24a H↑2,6a; L↑6,24a L↓6; HL↓24a HL↓24 H↑6,24
USP7 HL↓6; H↑24 HL↓6,24a H↓2,6a,24a; L↓6 NC H↓24
SMUG1 H↓2; HL↓6; H↑24a; L↑24 H↑24a; L↑24d HL↑24a NC NC
MTHFR NC NC NC NC NC
MTHFD1 H↓24a; L↓24 H↓24b H↓6a,24a; L↓24 HL↓24 NCd
MTR NC HL↓6; H↓24a H↓6a,24a; L↓6 H↓24a; L↓24 H↓6,24ad
MTRR H↑6a,24a L↓24a H↑6a; L↓24 NC H↑6
CBS H↑24b; L↑24a NC NC HL↓24a NC
TCN2 NC NC H↑24b NC NC
SHMT1 H↓24a H↓24a HL↓24 HL↓24 NC
TYMS H↓24a; L↓24 H↑2,6a; L↑6 HL↓2; H↓6b,24b; L↓6a,24a HL↓24 H↑24
DHFR H↓24b; L↓24a H↑2, 24a; HL↑6 HL↓24b HL↓24 H↑6; L↑24
BHMT NC H↑24 NC NC NC
CTH H↑6b; L↑6a; HL↑24b H↑6a,24b H↑2a,6b,24b; L↑6a,24a NC H↑6,24bd
AHCY H↓24a; L↓24 HL↑6; L↑24 H↓24a; L↓2,6,24 HL↓24 H↑6
ALDH1L1 NC NC NC NC NC
ATIC H↓6; HL↑24 H↓24a; L↓24 H↓6a,24a; L↓2,6,24 NC NC
GART HL↑24 H↓6a,24a; L↓24 H↓6a,24a; L↓6,24 HL↓24d NC
MTHFS NC H↓24a H↓2; HL↓6a; H↓24b; L↓24b NC NC
FTCD H↓24 NC H↑24c NC NC
MAT1A NC NC NC NC NC
MAT2A H↓6,24a H↓6a,24b; L↓6,24 NC NC H↓24a
MAT2B H↓24; L↓2 NC H↑2a; L↑2; HL↑6 NC NC
NNMT NC NC H↓2c,6b; L↓2,6a NC NC
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overall independent of the cancer type in which the drug
activity is tested. These concerted changes may therefore
provide a basis for using potential drug combinations in a
spectrum of tumors.
Concerted patterns of expression changes in response to
multiple agents
A number of genes with important biological roles had
consistent concerted changes in expression after treatment
by different antitumor agents. DNMT1, the maintenance
DNA methyltransferase, was downregulated after treatment
with 5-azacytidinine, doxorubicin, vorinostat, and paclitaxel
(Table 1; Fig. 1), suggesting that cellular response to these
drugs may involve possible reduction in DNA methylation
mediated by DNMT1. MGMT expression was diminished
after treatment with 5-azacytidinine, doxorubicin, and
cisplatin. MGMT is involved in DNA demethylation and
repair and in cellular resistance to cancer drug treatment
(Additional file 1: Table S1) [40, 52]. Downregulation of
MGMT decreases the ability of its product to repair DNA
lesions after treatment with antitumor agents, leading to
cancer cell death [40]. In contrast, GADD45A was con-
sistently upregulated after treatment with each of the
five drugs (Table 1; Additional file 2: Figures S2 and
S7). GADD45A encodes a DNA repair-mediated DNA
demethylating factor that can reactivate genes which
had been silenced by methylation, and it is involved in
apoptosis [8, 32, 53, 54].
Genes encoding methyl-CpG binding proteins (MBD1,
MBD2, MBD3, MBD4, and MeCP2) had different re-
sponses to antitumor agents (Table 1; Additional file 2:
Figures S2, S7 and S11). MBD1 was consistently upregu-
lated after treatment with each of the five drugs. MBD2,
MBD3, and MeCP2 were each downregulated by between
one and three antitumor agents that include 5-azacytidine,
doxorubicin, and vorinostat. Expression changes of MBD4
were time- and drug-specific, with some treatment condi-
tions resulting in its upregulation and others in downregu-
lation. Products of these genes have different binding
modes to methylated and unmethylated DNA, and they
play different roles in transcriptional activation, transcrip-
tional repression, DNA repair, and DNA demethylation
(Additional file 1: Table S1) [1, 4, 10, 55–57]. Consistent
upregulation of MBD1 after treatment by each of the five
drugs and downregulation of MBD2, MBD3, and MeCP2
after treatment by certain antitumor agents demonstrate
their different biological roles in epigenetic response to
cancer treatment.
SLC19A1, the gene for reduced folate carrier (RFC) in the
OCM pathway, was consistently downregulated in response
to each of the five agents (Table 1). It encodes a major fol-
ate transporter across cell membrane, which is an import-
ant target for antifolate drugs [14, 15, 27, 29, 58, 59]. Its
downregulation suggests that each of the anticancer drugs
used in this study may have additional cellular effects by
affecting the folate-mediated OCM pathway.
Table 1 Summary of time-specific drug treatment effects on gene expression in the NCI-60 cell lines (Continued)
PON1 NC NC NC NC NC
SLC19A1 HL↓24 H↓6a; HL↓24a H↓6a; L↓6; HL↓24a L↓24 H↓24
FOLR1 NC NC H↑24b NC NC
FOLR2 NC H↑24ad NC NC NC
FOLR3 NC NC NC NC NC
SHMT2 H↑6; HL↑24a H↑6; H↓24a H↓24a; L↓24 HL↓24 H↑6
AMT H↓6 HL↑24 H↑24a NC NC
MTHFD2 H↑6a; L↑6; HL↑24a NC HL↓24a L↓24a H↑6,24a
MTHFD2L NC H↓6a,24b; L↓24a NC NC H↓24a; L↑2
PEMT NC HL↓24a HL↓6a,24a NC H↓24a; L↓24
FOLH1 H↓24a NC NC NC NC
ALDH2 NC H↑6; HL↑24a HL↑6a; H↑24a NC NC
Information about gene roles is provided in Additional file 1: Table S1. Concerted changes in expression (↑, upregulated or ↓, downregulated) are shown for microarray
experiments in which nearly all cell lines had a change in the same direction, with no more than 15 cell lines showing a change in the opposite direction. Expression
changes are shown if observed for the high concentration only (H), low concentration only (L), or both high and low concentrations (HL) of each antitumor agent. The time
when the change was observed is also indicated. The drug concentrations for each agent are listed in the “Methods”. NC (not concerted), indicates that either the criteria of
concerted expression were not satisfied or that those criteria were not indicative of concerted expression due to a large amount of missing data for a specific gene in a given
microarray experiment. For example, H↑2,6a; HL↓24 indicates that a gene was upregulated after treatment with the high concentration of the drug at 2 and 6 h after
treatment, with the change of log2 expression values at 6 h in at least some cell lines being ≥1 or ≤−1, and that the same gene was downregulated at both high and low
concentrations of the drug at 24 h after treatment
aConcerted expression change as described above and log2 FC (the difference of log2 expression values between treated and untreated cells) in that direction in
some cell lines was ≥1 or ≤−1
bConcerted expression change and log2 FC in that direction in some cell lines was ≥2.5 or ≤−2.5
cConcerted expression change as described above and log2 FC in that direction in some cell lines was ≥4 or ≤−4
dFor at least one drug concentration and at least one time point, changes in expression were significantly correlated with log(GI50) as shown in Table 2
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Fig. 1 (See legend on next page.)
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Several other OCM genes were downregulated in re-
sponse to multiple agents (Table 1; Additional file 2:
Figures S1-S2, S5, S8, S9, S12, S13, and S15). For
example, the expression of MAT2A was diminished
after treatment with 5-azacytidine, doxorubicin, and
cisplatin. Its product, L-methionine S-adenosyltrans-
ferase IIα, catalyzes biosynthesis of SAM, the major
source of methyl groups for methylation reactions
(Additional file 1: Table S1) [60], and inhibition of
MAT2A inhibits the production of SAM and sup-
presses methylation processes [61]. MTHFD1, which
encodes methylenetetrahydrafolate dehydrogenase 1,
was downregulated by 5-azacytidinine, doxorubicin,
vorinostat, and paclitaxel, whereas MTR, the gene for
methionine synthase, was downregulated by doxorubi-
cin, vorinostat, paclitaxel, and cisplatin.
CTH was strongly upregulated after treatment with
5-azacytidinine, doxorubicin, vorinostat, and cisplatin
(Additional file 2: Figure S3). Such upregulation is
consistent with the role of its protein, cystathionase,
in irreversible degradation of cystathionine, which is
derived from Hcy, to cysteine. This transsulfuration path-
way removes Hcy from the remethylation cycle and makes
it unavailable for methylation reactions [15, 62, 63].
For some other genes in the OCM pathway, the direction
of concerted expression changes was specific to individual
agents (Table 1). For example, the expression of GART,
which is involved in purine biosynthesis (Additional file 1:
Table S1), was increased after treatment with 5-azacytidine
but diminished after treatment with doxorubicin, vorino-
stat, and paclitaxel. TYMS and DHFR, which encode im-
portant antifolate drug targets thymidylate synthase and
dihydrofolate reductase, respectively, were downregulated
in a concerted manner after treatment by 5-azacytidinine,
vorinostat, and paclitaxel, but upregulated after treatment
with doxorubicin and cisplatin (Table 1; Fig. 2; Additional
file 2: Figure S4). TYMS catalyzes the conversion of deox-
yuridine monophosphate (dUMP) into deoxythymidine
monophosphate (dTMP), which serves as a precursor for
DNA synthesis and is used DNA repair (Additional file 1:
Table S1). This reaction produces dihydrofolate (DHF), the
reduction of which to THF is catalyzed by DHFR [18, 64].
Downregulation of several OCM genes including TYMS
was previously noted after treatment of patient samples
and cell lines of childhood B-lymphoblastic leukemia
and of colon cancer cell lines with vorinostat [65, 66].
Furthermore, upregulation of TYMS and DHFR was a
part of a gene expression signature that has been asso-
ciated with relapse of acute lymphoblastic leukemia, and
reversal by vorinostat of expression pattern of signature
genes including TYMS and DHFR restored B-cell chemo-
sensitivity to treatment [65]. Similarly, downregulation of
TYMS by vorinostat has been critical in increasing the
sensitivity of colorectal cancer cell lines to antifolate drugs
and for overcoming chemoresistance [67]. Our results
demonstrate that in addition to vorinostat, other anti-
cancer drugs analyzed in this report also affect import-
ant reactions in the OCM pathway (Table 1), which
may affect cytotoxic effects of these agents. Upregulation
of TYMS and DHFR after treatment with doxorubicin and
cisplatin suggests that it may be beneficial to target these
genes in combination therapy treatments. Vorinostat and
doxorubicin have synergistic cytotoxic action [68], and it
could be postulated that downregulation of TYMS and
DHFR by vorinostat may contribute to synergy between
these drugs.
Interestingly, while DGIdb and PharmGKB reported
interactions with paclitaxel and cisplatin for MTHFR
encoding 5, 10-methylenetetrahydrofolate reductase that
catalyzes one of the central OCM pathway reactions
(Additional file 1: Table S1) [14, 18], its expression did
not satisfy the criteria for concerted changes after treatment
with any of the five agents (Table 1), although it showed a
trend for upregulation at 2 h after treatment with the high
concentration of paclitaxel (data not shown).
Of the genes listed in Table 1, NNMT, the gene for
nicotinamide N-methyltransferase, demonstrated the
largest amplitude of expression changes after treatment
with 5-azacytidine (log2 FC <−6 and log2 FC >7 for some
cell lines, where FC is fold change), doxorubicin (log2
FC reaching >5), and vorinostat (log2 FC <−7 and log2
FC >6 for some cell lines). Among the five agents,
NNMT had concerted changes in expression only after
treatment with the high concentration of vorinostat
(Table 1), and the magnitude of its expression changes
did not correlate with the direction of response to any of
the agents or with chemosensitivity. Overexpression of
NNMT in cancer cells reduces the cell methylation po-
tential and leads to histone hypomethylation [69, 70].
The biological significance of the very strong expression
response of NNMT to cancer drug treatment remains to
be elucidated.
(See figure on previous page.)
Fig. 1 Changes in the expression of the DNMT1 methyltransferase gene in the NCI-60 cell line panel. Shown are transcriptional changes of the
DNMT1 gene at 2 (left panel), 6 (middle panel), and 24 h (right panel) after treatment with high concentrations of a 5-azacytidine (5000 nM), b
doxorubicin (1000 nM), c vorinostat (5000 nM), and d paclitaxel (100 nM). Horizontal right bars indicate elevated gene expression, whereas left bars
indicate decreased expression relative to cell lines untreated by the drug. Colors represent types of cancer tissues (breast, central nervous system
(CNS), colon, leukemia, lung, melanoma, ovarian, prostate, and renal cancers). The scale on the bottom represents log2 difference between expres-
sion values of treated and untreated cell lines. The scale for each microarray experiment is specific to that experiment
Krushkal et al. Clinical Epigenetics  (2016) 8:73 Page 7 of 24
Fig. 2 Drug-specific response patterns of changes in the expression of the TYMS gene. Shown are changes in the expression of the TYMS gene at 2
(left panel), 6 (middle panel), and 24 h (right panel) after treatment with high concentrations of a 5-azacytidine (5000 nM), b doxorubicin
(1000 nM), c vorinostat (5000 nM), d paclitaxel (100 nM), and e cisplatin (15,000 nM). Additional information is provided in the legend to Fig. 1
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Downregulation of DNMT1 and concerted changes in the
expression of multiple other epigenetic components and
OCM genes in response to 5-azacytidine
5-Azacytidine exerts its hypomethylating action by
directly targeting the maintenance DNA methyltransfer-
ase DNMT1, depleting its amount in the cell by both
covalent binding and by DNA replication-independent
mechanisms [1, 71]. In the NCI-60 cell lines, the DNMT1
gene was downregulated at 24 h at both high (Fig. 1a)
and low concentrations of 5-azacytidine, whereas neither
DNMT3A nor DNMT3B showed concerted changes in
expression (Table 1). The observed downregulation of
DNMT1, the lack of concerted changes in the expression
of DNMT3B, and transcriptional activation of the
apoptotic pathway were in agreement with earlier re-
ports [1, 32, 53]. At 24 h, we did not observe downreg-
ulation of DNMT3A in the HCT-116 cell line after
treatment with the low concentration (log2 FC = 0.228), in
contrast to an earlier study [32], although we observed a
minimal downregulation (log2 FC = −0.197) of DNMT3A
in that cell line after treatment with the high concentra-
tion of 5-azacytidine.
Of the three TET family dioxygenases that convert 5-
methylcytosine (5-mC) to 5-hydroxymethylcytosine (5-
hmC), 5-formylcytosine (5-fC), and 5-carboxylcytosine
(5-caC) [1, 6], expression data were available for TET3,
which was upregulated at 24 h after treatment with the
high concentration (Table 1; Additional file 2: Figure
S1). TDG, another component of the DNA demethyla-
tion pathway, was also upregulated (Additional file 2:
Figure S2). This suggests that upregulation of TET3 and
TDG may increase the rate of DNA demethylation and
contribute to the demethylating action of 5-azacytidine.
It was previously suggested [52] that hypomethylat-
ing agents targeting DNA methyltransferases may
restore the activity of MGMT and thereby increase
antidrug resistance. The data in Table 1 show that
MGMT was downregulated at 24 h, indicating at
least an initial decrease in MGMT transcription.
GADD45A was strongly upregulated (Additional file
2: Figures S1 and S2), in agreement with its role in
mediating TP53-induced apoptosis [32, 53] and its
possible synergistic contribution to the demethylating
action of 5-azacytidine [54]. Strong upregulation of
GADD45A was previously reported in the Molecular
Signatures Database (MSigDB) as part of molecular
signature characteristic of breast cancer cell line re-
sponse to 5-azacytidine [72] via demethylation of
GADD45A promoter after treatment [73].
The expression of APOBEC3C was diminished at 24 h
after treatment. APOBEC3C participates in DNA
demethylation by reducing the levels of 5hmC, but
members of the APOBEC family are also involved in
DNA repair (Additional file 1: Table S1) [74]. Therefore, it
may be possible that downregulation of APOBEC3C may
contribute to cell death through diminished DNA repair.
After treatment with 5-azacytidine, MBD1 was upregu-
lated, MBD2 was downregulated, while expression changes
of MBD4 were time-dependent (Table 1; Additional file 2:
Figures S1 and S2). The differences in their expression
changes are likely related to their different biological roles.
Expression patterns of several other epigenetic factors
including PCNA, USP7, and SMUG1, which may affect
DNA methylation, DNA demethylation, and DNA repair
(Additional file 1: Table S1) [1, 6, 11, 74–76], changed with
time (Table 1; Additional file 2: Figure S2). While IDH1
expression did not satisfy the criteria for concerted
changes, IDH2 was downregulated at 24 h after treatment
with the high concentration of 5-azacytidine, suggesting
differences in their regulation. These changes illustrate the
dynamic nature and complexity of regulation of epigenetic
changes and DNA repair and replication following drug
treatment.
Many important OCM genes including TYMS, DHFR,
AHCY, FTCD, MAT2A, MAT2B, and AMT were down-
regulated after treatment with 5-azacytidine (Table 1;
Fig. 2, Additional file 2: Figures S1, S2, and S4). TYMS
and DHFR are important drug targets [27], and their
downregulation is important for cytotoxicity of cancer
drug treatment [65, 67]. MAT2A and MAT2B, the
components of the L-methionine S-adenosyltransferase
II, and AHCY, the S-adenosyl-L-homocysteine hydro-
lase, are involved in the control of the levels of SAM
and SAH, which are important for methylation reac-
tions [60, 61, 63, 77, 78]. FOLH1, which is involved in
intestinal absorption of dietary folate and in its conver-
sion to folate, affecting folate levels in vivo [79], was
also downregulated. Hypermethylation of the FOLH1
promoter has been associated with the risk of relapse
and poor clinical outcomes of childhood neuroblastoma
[80]. The role of FOLH1 in in vitro cellular response
requires further elucidation.
SLC19A1, which is involved in folate transport, was
downregulated, whereas none of the folate receptor
genes involved in folate endocytosis satisfied the criteria
for concerted expression changes. These results are in
agreement with earlier studies [73, 81], which demon-
strated the effect of demethylating agents 5-azacytidine
and decitabine on transcription, promoter methylation,
and protein expression of SLC19A1 but not of the folate
receptor genes.
Among the upregulated OCM genes were CBS and
CTH, which participate in the conversion of Hcy to
cysteine, removing Hcy from the methylation cycle
[15], MTRR, and GART (Table 1; Additional file 1:
Table S1; Additional file 2: Figures S1 and S3). GART
is an element of the purine biosynthetic pathway, and its
increased expression may predict poor outcome in glioma
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and hepatocellular carcinoma [82, 83]. This suggests that
GART may be examined as a potential target in drug com-
binations that include 5-azacytidine, in order to enhance
the treatment effect by using an additional agent that
would suppress purine biosynthesis (Additional file 1: Table
S1). The changes in the expression of ATIC, which is also
involved in purine biosynthesis, were time-dependent
(Table 1). SHMT2 andMTHFD2, the products of which are
involved in the OCM pathway in mitochondria, were up-
regulated. In contrast, SHMT1 and MTHFD1, the products
of which regulate an analogous set of cytoplasmic reactions,
were downregulated (Table 1; Additional file 1: Table
S1) [18, 84]. This indicates compartmentalization of
folate metabolism in response to this drug.
To examine the downstream cellular effects of expression
changes in methylation machinery, we analyzed the
expression changes of 91 potential target genes at 24 h
after treatment with the high concentration of 5-
azacytidine (Additional file 2: Figure S1), when the
most profound expression changes were observed. In
agreement with earlier reports [32, 53] that suggested
links between the downregulation of DNMT1 by 5-
azacytidine, TP53-mediated apoptosis, and changes in
the expression of DNA damage response genes, we
observed strong upregulation of CDKN1A (p21) which
is involved in cell cycle arrest, and upregulation of
TP53 and BAK1, which are involved in apoptosis,
although these early increases are likely to be in response
to DNA damage [85]. We also observed changes in the
expression of multiple other cancer-related genes
(Additional file 2: Figure S1). Many upregulated genes
that are involved in DNA damage response, DNA
repair, maintenance of genome integrity, and cell growth
arrest have been reported to be reactivated after treatment
due to changes in their methylation status [53, 65, 86].
While gene re-expression induced by DNA demethylation
is generally believed to take 3–7 days, some reports indicate
that it can happen as early as at 12–24 hours after treat-
ment [87–89]. Among genes induced by 5-azacytidine in
some of the cell lines was PTEN, the expression of which is
induced by demethylation of its promoter after treatment
[90]. RASSF1, which is involved in cell cycle control and
microtubule stabilization, was also moderately upregulated.
As its isoform, RASSF1A, is silenced by DNA methylation
in tumor cells [91–93], it is possible that RASSF1 expres-
sion was reactivated through hypomethylation after treat-
ment with 5-azacytidine and may contribute to improved
outcome in response to treatment.
Concerted changes in the expression of DNA
methyltransferase genes, other epigenetic factors, and
multiple OCM genes in response to doxorubicin
Treatment of the HCT-116 cell line with 1 μM of doxo-
rubicin has been reported to inhibit DNMT1 activity
and to cause conditional apoptosis [34]. In our dataset,
at 6 and 24 h after treatment with 1 μM of doxorubicin,
both DNMT1 and DNMT3B genes were downregulated
in the majority of the cell lines (Table 1; Fig. 1b;
Additional file 2: Figure S6A). Therefore, doxorubi-
cin both inhibits activity and downregulates these
DNA methyltransferases, indicating robust inhibition
of methylation. Interestingly, while DNMT3A did not
satisfy the criterion for concerted expression changes, it
showed a strong trend for upregulation in the majority of
the cell lines at 24 h (data not shown), suggesting that it
may be considered as a potential target for combination
therapy with doxorubicin and an additional agent target-
ing this specific DNA methyltransferase.
APOBEC3C, GADD45A, and IDH2, which are involved
in or generate products that interfere with DNA demethyl-
ation, were upregulated after treatment (Additional file 2:
Figures S5 and S7). The response of IDH1 was time-
specific (Table 1), and the expression of MGMT was
diminished. Among the genes encoding methyl-CpG-
binding domain proteins, MBD1 and MBD4 were up-
regulated, and the expression of MBD2 and MeCP2 was
diminished, underlying differences in their regulation
and action (Table 1; Additional file 1: Table S1; Additional
file 2: Figures S5 and S7). USP7 was downregulated,
whereas PCNA was upregulated. SMUG1 was also upreg-
ulated, and the change in its expression was negatively
correlated with chemosensitivity (Tables 1 and 2). SMUG1
encodes a DNA demethylating and DNA repair agent that
participates in the base excision repair (BER) pathway
[1, 6, 74, 94] (Additional file 1: Table S1). Its upregula-
tion indicates active BER pathway response to doxorubicin-
induced DNA damage and suggests that targeting SMUG1
in combination therapy might increase doxorubicin activity
by increasing cell susceptibility to DNA damage.
Among the components of the OCM pathway, we ob-
served strong concerted downregulation of MTR, MTRR,
MAT2A, MTHFD1, SHMT1, and MTHFS (Table 1). Also
downregulated were ATIC and GART, regulators of
purine biosynthesis, MTHFD2L which participates in the
OCM pathway in mitochondria [18], and PEMT, the
product of which catalyzes the de novo synthesis of
phosphatidylcholine using SAM as methyl donor
(Additional file 1: Table S1) [63].
CTH, BHMT, AHCY, AMT, ALDH2, and multiple
other OCM genes were upregulated (Table 1; Additional
file 1: Table S1). BHMT has been reported to have a
protective role against cancer, and its absence promotes
malignancies in the liver [64, 95]. Inhibition of AHCY
has been associated with DNA hypomethylation and
cancer progression, whereas its upregulation contributes
to apoptosis and cell differentiation [63, 96]. While the
function of ALDH2 has been associated with folate levels
in vivo [97], upregulation of this gene, in accord with
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our measurements, was found to be a part of an MSigDB
molecular signature in mouse cell lines undergoing apop-
tosis in response to doxorubicin [72, 98]. Other upregu-
lated genes included TYMS and DHFR (Table 1; Fig. 2;
Additional file 2: Figures S4, S5 and S8), suggesting that
they could be considered as targets in combination drug
therapy with doxorubicin.
Although ALDHD1L1 did not satisfy the criterion for
a concerted change, it showed a trend for increased
expression at 24 h after treatment with the high concen-
tration (data not shown), in agreement with earlier reports
[72, 98]. This may have clinical importance because its
product is a major regulator of availability of folate-bound
carbon groups for cellular processes, affecting the avail-
ability of methyl groups (Additional file 1: Table S1)
[17, 99]. ALDH1L1 is epigenetically silenced in cancers,
and its upregulation induces cytotoxicity and apoptosis
[17, 99], suggesting that its increased expression in
specific cell lines after treatment may contribute to the
antitumor action of doxorubicin.
The expression of FOLR2 was increased at 24 h after
treatment with the high concentration of doxorubicin,
and this increase was negatively correlated with chemosen-
sitivity (Table 2). The folate transporter gene, SLC19A1,
was downregulated, whereas neither FOLR1 nor FOLR3 re-
ceptor genes showed concerted expression changes. These
results are in agreement with earlier studies that suggested
the distinctive role of FOLR2 in the cytotoxicity of
folate-targeted doxorubicin [100]. Additionally, mul-
tiple expression changes listed in Table 1 in response to
doxorubicin confirm earlier reports that downregula-
tion of MBD2, MECP2, and SLC19A1 and upregulation
of GADD45 and ALDH2 were a part of an MSigDB mo-
lecular signature in mouse cell lines undergoing apop-
tosis in response to the high concentration (1000 nM)
of doxorubicin [72, 98].
When potential target genes of epigenetic regulation
were examined, at 24 h after treatment with the high
concentration of doxorubicin, we observed an upregula-
tion of a number of tumor suppressor genes and other
genes involved in DNA replication and repair, cell growth
arrest, and inhibition of cell proliferation (Additional file
2: Figure S5). Changes in the expression of DDB2 and
CDKN1A correlated with chemosensitivity to the low
concentration of doxorubicin at 24 h (r = −0.568, FDR
corrected p = 0.0046 for DDB2 and r = −0.489, p = 0.0284
for CDKN1A). An earlier study showed that the expres-
sion of DDB2, which is involved in response to DNA dam-
age, is induced by doxorubicin, and the level of that
response and cell sensitivity to doxorubicin were regulated
by BRCA1 [101]. In our study, transcriptional changes of
BRCA1 were only weakly correlated with chemosensitivity
to doxorubicin (r between −0.335 and 0.254), but the
inverse correlation of expression changes of its target,
DDB2 with log(GI50) confirmed the importance of the
DNA damage response pathway in chemoresistance to
this agent. It remains to be determined whether these
expression changes were induced through direct tran-
scriptional regulatory response to DNA damage or via epi-
genetic regulatory mechanisms.
Hypermethylation of GSTP1 and ABCB1 has been sug-
gested to predict chemosensitivity to doxorubicin [41].
GSTP1 was upregulated at 6 and 24 h after treatment
with the high concentration and at 24 h after treatment
with the low concentration of the agent, whereas ABCB1
had variable patterns of expression among cell lines. How-
ever, correlation of expression changes of both GSTP1 and
ABCB1 with chemosensitivity was weak (r between −0.3
and 0.35).
Treatment of the HCT-116 cell line with high concen-
trations of doxorubicin inhibits DNMT1 and leads to
apoptosis [34]. Induction of apoptosis by doxorubicin
Table 2 Candidate genes involved in DNA methylation, demethylation, and one-carbon metabolism, for which expression changes
were significantly correlated with chemosensitivity or chemoresistance to drug agents
Gene Antitumor agent Drug concentration and time after treatment r FDR adjusted p value
FOLR2 Doxorubicin High, 24 h −0.509 0.0366
SMUG1 Doxorubicin Low, 24 h −0.488 0.0284
GART Paclitaxel Low, 24 h 0.462 0.0422
GADD45A Cisplatin High, 24 h −0.618 0.0011
GADD45A Cisplatin Low, 24 h −0.477 0.0422
MBD1 Cisplatin High, 24 h −0.570 0.0046
MTR Cisplatin High, 24 h 0.564 0.0046
MTHFD1 Cisplatin High, 24 h 0.552 0.0061
CTH Cisplatin High, 24 h −0.531 0.0122
CTH Cisplatin Low, 24 h −0.504 0.0234
Listed are genes involved in DNA methylation, demethylation, and the OCM pathway which satisfied FDR adjusted p <0.05 for Pearson correlation of their
expression changes with chemosensitivity
r Pearson coefficient of correlation of log2 FC with log(GI50) values across NCI-60 cell lines
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occurs via a TP53-dependent mechanism [102], consistent
with upregulation of TP53 in our study. Because treatment
with doxorubicin leads to extensive changes in the expres-
sion of genes encoding DNA methyltransferases and genes
involved in DNA demethylation, further studies are needed
to examine whether doxorubicin-induced silencing and re-
activation of tumor suppressor genes and genes involved in
cell cycle control and DNA repair (Additional file 2: Figure
S5) are modulated by DNA methylation processes or by
other regulatory mechanisms that are independent from
DNA methylation and demethylation.
The T-47D breast cancer cell line is resistant to doxorubi-
cin [102]. We observed a distinct pattern of expression
changes in the T-47D cell line in response to this agent,
which was very different from all other NCI-60 cell lines
(Additional file 2: Figures S5-S8), suggesting unique fea-
tures in its biological response to doxorubicin.
Strong concerted expression changes among components
of epigenetic and folate-mediate OCM pathways in response
to vorinostat
Vorinostat and other HDAC inhibitors lead to cell differ-
entiation, inhibition of cell growth, apoptosis mediated
by inhibition of DNMT1, and global and gene-specific
DNA hypomethylation [36].
In agreement with earlier reports [36, 65, 66], treatment
with vorinostat led to marked changes in the expression of
many genes with biological roles outside the histone
modification pathways. This included extensive consistent
expression changes among components of DNA methyla-
tion and demethylation pathways and among members of
the OCM pathway (Table 1; Figs. 1 and 2; Additional file
2: Figures S3C, S4C, S6B, and S9-S12).
We observed concerted downregulation of DNA
methyltransferase genes DNMT1, which confirmed an
earlier report [36], and DNMT3A (Table 1; Figs. 1c and
2a). Interestingly, DNMT3B was upregulated at 2 and
6 h after treatment (Additional file 2: Figure S6B). The
biological implications of the short-term upregulation
of DNMT3B in response to vorinostat require further
investigation.
GADD45A was upregulated. Expression of several
other genes involved in demethylation, including
TET3, APOBEC3C, and TDG, was diminished (Table 1;
Additional file 2: Figures S9 and S11). While it did not
satisfy the criterion for a concerted change, MGMT
showed a trend for downregulation at 24 h in the ma-
jority of the cell lines (data not shown). The dimin-
ished expression of TDG, APOBEC3C, and MGMT
may increase susceptibility of cancer cells to treatment
due to reduced DNA repair, as vorinostat has been
shown to induce ROS and DNA damage [103]. Mul-
tiple other epigenetic components also demonstrated
strong concerted expression changes (Table 1).
In agreement with previous studies [65, 66], we observed
strong downregulation of multiple folate metabolism genes
including MTHFD1, MTR, SHMT1, TYMS, DHFR, AHCY,
ATIC, GART, MTHFS, SLC19A1, PEMT, NNMT, and com-
ponents of mitochondrial pathways, SHMT2 and MTHFD2
(Table 1; Fig. 2c; Additional file 2: Figures S4C, S9 and
S12). These changes suggest downregulation of SLC19A1-
mediated folate transport and of reactions that result in
nucleotide and DNA synthesis, DNA repair, biosynthesis of
phosphatidylcholine, or provide methyl groups for cellular
methylation processes (Additional file 1: Table S1). At 24 h,
TYMS expression in many cell lines dropped to the levels
of log2 FC <−2, with changes in the SF-295 cell line reach-
ing log2 FC = −3.68. Downregulation of TYMS, DHFR, and
ATIC is clinically important for the cytotoxic effects of
cancer treatment [65, 67].
TCN2 and CTH (Additional file 2: Figure S3C) were
strongly upregulated after treatment with the high con-
centration of vorinostat (maximum log2 FC = 3.13 for
TCN2, 3.69 for CTH at 24 h). The latter suggests the in-
crease in removal of Hcy from methylation cycle. The
expression of FTCD was also increased, with very strong
upregulation (log2 FC >4) in several renal and ovarian
cancer cell lines at 24 h after treatment with the high
concentration. Among other upregulated genes were
MAT2B, AMT, ALDH2, and FOLR1 (Additional file 2:
Figures S9 and S12). Changes in MTRR expression were
time-dependent (Table 1).
Among potential methylation targets, at 24 h after
treatment with the high concentration of vorinostat,
we observed some level of upregulation of the tumor
suppressor gene DLC1 and moderate downregulation
of TERT in most of the cell lines (Additional file 2: Figure
S9), in agreement with their previously reported expres-
sion response to vorinostat due to methylation changes
[36–38]. The expression of TP53, which had been sug-
gested to have a synergistic effect with downregulation of
TYMS in chemosensitivity to drug therapy [67], was
strongly diminished in the majority of the cell lines at 6
and 24 h after treatment with high and low concentra-
tions. The direction of change in abundance of the p53
protein in colorectal cancer cell lines has been reported to
depend on vorinostat concentration and TP53 mutation
status [67]. However, p53 protein abundance and activity
are regulated by acetylation [67, 68]. Therefore, mech-
anisms and consequences of strong transcriptional
downregulation of TP53 after treatment with vorinostat
require further investigation. Multiple other cancer-
related genes also showed strong changes in expres-
sion (Additional file 2: Figure S9). In addition to
possible DNA methylation changes, their expression
may be regulated by vorinostat via other mechanisms
including histone acetylation and changes in miRNA
expression [37].
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Concerted changes in expression of several components
of DNA methylation machinery and downregulation of
multiple components of the OCM pathway in response to
paclitaxel
As a general trend after treatment with paclitaxel, transcrip-
tional changes among components of DNA methylation
and demethylation pathways and the OCM pathway were
not as strong or as concerted as those after treatment with
other antitumor agents investigated in this study (Table 1;
Additional file 2: Figure S13). However, several genes dem-
onstrated concerted transcriptional changes, including
downregulation of DNMT1, IDH1, IDH2, and PCNA
(Table 1; Fig. 1d; Additional file 2: Figures S13 and S14) and
upregulation of DNA demethylating agents TDG and
GADD45A, and of the methyl-CpG-domain binding
protein 1, MBD1.
Expression of a number of important components of
the folate-mediated OCM pathway was diminished, with
the majority of downregulation observed at 24 h (Table 1).
Among the downregulated genes were MTHFD1, MTR,
CBS, SHMT1, TYMS, DHFR, AHCY, GART, SLC19A1,
SHMT2, and MTHFD2 (Fig. 2d; Additional file 2: Figures
S4D, S13 and S14), suggesting that treatment with pacli-
taxel may inhibit reactions that involve folate intake, DNA
synthesis, and synthesis of phosphatidylcholine (Additional
file 1: Table S1). Expression changes in GART were signifi-
cantly correlated with chemosensitivity (Table 2), and as
GART expression is associated with poor prognosis in
several cancers [82, 83], this might indicate a particular
requirement for purine biosynthesis in response to drug
treatment. None of the OCM genes satisfied the criteria for
concerted upregulation; however, several genes, most not-
ably MTHFS at 2 h after treatment, demonstrated a trend
for upregulation among the majority of the cell lines (data
not shown).
Among the potential methylation targets, RASSF1 was
predominantly upregulated (Additional file 2: Figure S13).
Its RASSF1A isoform has been reported to participate in
microtubule stabilization with the effect similar to that of
paclitaxel, and to be silenced by DNA hypermethylation,
and both RASSF1A and RASSF1C isoforms act as tumor
suppressors and contribute to cell death [93].
Methylation of the stratifin gene, SFN, has been asso-
ciated with progression-free survival of ovarian cancer
patients after treatment with paclitaxel-carboplatin ver-
sus docetaxel-carboplatin [49]. No concerted expression
changes of SFN were observed in our study, and while
there was some trend for its upregulation at 24 h after
treatment with the high concentration of paclitaxel,
transcriptional changes of SFN did not correlate with
chemosensitivity (r between −0.188 and 0.088).
Four cell lines, DU-145, SF-295, CAKI-1, and SF-268,
showed a trend for a reverse pattern of transcriptional
response to paclitaxel when compared to the majority of
other cell lines including PC3 (Additional file 2: Figure
S13). This is consistent with a suggestion [104] that the
differences between response of the DU-145 and PC3
cell lines to paclitaxel involve phosphorylation of the p16
protein in DU-145, which leads to apoptosis, whereas the
PC3 cells undergo a rapid mitotic slippage and have a
defective post-mitotic checkpoint. These observations and
a weak transcriptional response among components of
epigenetic machinery suggest that transcriptional changes
of many cancer-related genes in response to paclitaxel are
likely regulated by mechanisms other than DNA methyla-
tion or demethylation.
Expression response of several epigenetic factors and
OCM genes to cisplatin
In agreement with previous reports and molecular sig-
natures in MSigDB [72, 105, 106], after treatment with
cisplatin the expression of GADD45A, APOBEC3C,
TDG, IDH2, MBD4, and PCNA was increased, and at
24 h, the changes in the GADD45A expression were
significantly correlated with chemosensitivity (Tables 1
and 2; Additional file 2: Figure S16). The strongest
upregulation of GADD45A was observed at 24 h after
treatment with the high concentration, and in some
cell lines, it reached log2 FC >3. MBD1 was also upregu-
lated at 24 h after treatment with the high concentration,
which was significantly negatively correlated with chemo-
sensitivity (Table 2). MGMT was strongly downregulated
(in some cell lines, log2 FC <−2.5 at 24 h after treatment
with the high concentration) (Table 1; Additional file 2:
Figure S16), consistent with published data [107], even
though MGMT is not involved in cisplatin adduct repair.
IDH1 and USP7 were also downregulated.
The OCM genes MTR, MAT2A, SLC19A1, and PEMT
were downregulated (Table 1), suggesting possible inhib-
ition of folate intake and of reactions leading to methio-
nine remethylation and biosynthesis of SAM and
phosphatidylcholine. Expression of multiple other import-
ant OCM genes including TYMS and DHFR was increased
(Table 1; Fig. 2e; Additional file 2: Figures S3D, S4E, S15
and S17). Increased expression of TYMS at 24 h after
treatment with cisplatin is in agreement with an earlier
report [106], and upregulation of TYMS and DHFR
suggests that they could be examined as potential tar-
gets in combination therapy with cisplatin. The two
mitochondrial isozyme genes, MTHFD2 and MTHD2L,
have different expression patterns that are specific to
developmental stage and tissue differentiation [84],
which may explain differences in their regulation in re-
sponse to cisplatin and to other agents (Table 1). Changes
in the expression of MTHFD1, MTR, and CTH were
significantly correlated with chemosensitivity (Table 2),
suggesting the importance of OCM reactions in cytotox-
icity of cisplatin.
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Treatment with cisplatin led to changes in the ex-
pression of multiple potential methylation target
genes (Additional file 2: Figure S15), and at 24 h,
transcriptional changes in many of those genes were
significantly correlated with chemosensitivity. The majority
of significant correlation was observed after treatment with
the high concentration, including PPP1R15A (r = 0.700, FDR
adjusted p = 1.24 × 10−5), DDIT3 (r =−0.584, p= 0.0042),
CEBPG (r = −0.567, p = 0.0046), RASSF1 (r = −0.555,
p = 0.0060), RARB (r = 0.535, p = 0.0113), POLA1 (r =
0.517, p = 0.0181), BTG2 (r = −0.507, p = 0.0234), and
ATXN3 (r = −0.499, p = 0.0284). Expression changes
of CEBPG were also correlated with chemosensitivity
to the low concentration of the agent (r = −0.520, p =
0.0148 at 24 h).
It remains to be investigated whether epigenetic modi-
fications play a role in modulating this transcriptional
response. For example, upregulation of PPP1R15A
(GADD34), which is involved in cellular stress response,
was highly significantly correlated with log(GI50). Increased
expression of PPP1R15A has been linked to enhanced cyto-
toxicity of cisplatin [108, 109], but not to DNA methylation
changes. In contrast, hypermethylation of FANCF, SFN,
MLH1, and TP73 has been associated with chemosensitivity
to cisplatin [41]. In our study, FANCF, a DNA damage re-
sponse gene, was upregulated at 2 h after treatment with
the low concentration and downregulated at 24 h after
treatment with the high concentration of cisplatin, but cor-
relation of its expression changes with chemosensitivity was
very weak (r between −0.2 and 0.2). Epigenetic silencing of
MLH1, which is involved in DNA mismatch repair, has also
been suggested to be among determinants of cisplatin re-
sistance [41, 44].MLH1 was upregulated at 24 h after treat-
ment with the low concentration of cisplatin, but
correlation between its expression changes and chemosen-
sitivity was weak (r between −0.307 and 0.222). SFN was
upregulated at 6 and 24 h after treatment with the high
concentration, but correlation of its expression changes
with log(GI50) was only modest (r between −0.376 at 2 h
and −0.387 at 24 h after treatment). No concerted expres-
sion changes or correlation with chemosensitivity were
observed for TP73.
Validation of patterns of gene expression changes in
response to 5-azacytidine, doxorubicin, vorinostat, and
paclitaxel in other datasets
The Connectivity Map (cmap) [110] utilizes gene ex-
pression measurements at 6 h after treatment with 5-
azacytidine, doxorubicin, vorinostat, and paclitaxel at
concentrations that exceed the highest concentration
of these agents in the Transcriptional Pharmacology
(TP) Workbench. At 6 h after treatment with paclitaxel, no
genes in our study satisfied conditions of concerted up- and
downregulation for the high concentration, and only one
gene (IDH1) had a concerted change at the low concentra-
tion, and therefore, no comparable searches could be
performed for that agent. When we analyzed the lists of
up- and downregulated genes (Table 1) after treatment with
5-azacytidine, doxorubicin, and vorinostat, cmap permuta-
tion analysis confirmed the concerted expression changes
for vorinostat that were observed in our study. When the
list of genes with concerted changes at 6 h after treatment
with the high concentration of vorinostat from Table 1 was
used as input, cmap analysis identified vorinostat as the sec-
ond highest ranking agent among 1309 agents in the cmap
database (permutation-based p = 0, enrichment measure =
0.892). The third ranking agent was found to be another
HDAC inhibitor, trichostatin A (p <10−6). Even though the
connections and the ranking of cmap gene lists are based
on the magnitude of expression response, whereas the
concerted changes in our study were determined based on
the high proportion of NCI-60 cell lines with expression
changes in the same direction, the gene lists for vorinostat
from both datasets were in strong agreement, due to
consistent concerted changes among the cell lines and the
strong magnitude of expression response to this agent
(Table 1). Neither 5-azacytidine nor doxorubicin was
among the top cmap hits when their respective up- and
downregulated gene lists from Table 1 at 6 h after treat-
ment with their high concentrations were investigated.
The differences in ranking the response to 5-azacytidine
and doxorubicin between the TP Workbench and cmap
may be related to different concentrations of these agents
in the two datasets, which could trigger different types of
cellular response (e.g., demethylating action or apoptosis
for different concentrations of 5-azacytidine [1]). These
differences may also be related to the different methods
for identifying up- and downregulated genes, as our gene
lists were based on concerted changes among the NCI-60
cell lines, as opposed to the cmap ranking that used the
magnitude of changes in a small number of individual cell
lines. Despite these differences, the second best ranking
agent in the Connectivity Map analysis of the gene signa-
ture composed of up- and downregulated genes at 6 h
after treatment with 1000 nM of doxorubicin (Table 1)
was another anthracycline antibiotic, daunorubicin [111]
(p = 0, enrichment = 0.948). This similarity was based on
cmap measures of transcriptional response at 6 h after
treatment with 1000 and 7000 nM of daunorubicin. This
suggests that cancer cell treatment with a lower concen-
tration of doxorubicin (1000 nM) than that available in
the cmap dataset for doxorubicin (6800 nM) elicits a re-
sponse similar to that of the comparable concentration of
daunorubicin.
Many experiments in the Library of Integrated
Network-Based Cellular Signatures (LINCS) also cor-
respond to higher concentrations of the cancer drugs
examined in this study than those in the TP Workbench.
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Despite these differences, our searches of LINCS data con-
firmed the validity of the lists of genes with concerted
changes identified in Table 1 for 5-azacytidine, doxorubicin,
vorinostat, and paclitaxel. When we used median log2 FC
values and the gene lists from Table 1, the LINCS
L1000 Characteristic Direction Signature Search En-
gine (L1000CDS2) search for 6 h after treatment with
the high concentration of 5-azacytidine returned LINCS
experiments corresponding to 6 h after treatment with
10,000 nM of 5-azacytidine as top hits. The L1000CDS2
search using our gene results from 24 h after treatment
with the high concentration of 5-azacytidine returned
LINCS experiments corresponding to 24 h after treatment
with 10,000 nM of 5-azacytidine as top hits, including the
second best hit of all experiments. The search by
L1000CDS2 using the list of genes in Table 1 from 24 h
after treatment with the low concentration of 5-azacytidine
returned experiments corresponding to 24 h after treat-
ment with 3300 and 3370 nM of 5-azacytidine among the
top hits. Interestingly, LINCS experiments involving nu-
cleoside analogs kinetin riboside and thiazolopyrimidine
were also returned among the top hits by the L1000CDS2
searches, whereas LINCS experiments involving inhibitors
of purine biosynthesis, mercaptopurine, and thioguanosine
were among the top LCD searches that used genes
from Table 1 with concerted expression response to
5-azacytidine. These results support the suggestion that
treatment with 5-azacytidine leads to concerted changes
in the expression of genes that affect nucleotide synthesis,
DNA biosynthesis, and DNA repair.
When we examined response to doxorubicin, L1000CDS2
identified LINCS experiments at 6 h after treatment with
10,000 nM of doxorubicin among the top hits for our
searches that utilized the lists of genes from Table 1 with
concerted changes at 6 h after treatment with the high
concentration of the agent and at 24 h after treatment
with the low concentration. L1000CDS2 searches that
used both the lists of concerted genes and their median
expression values returned LINCS experiments for
doxorubicin analogs, 10,000 nM of epirubicin and 800 nM
of 4-demethoxydaunorubicin, among the top hits for the
input gene signatures from Table 1 corresponding to 2 and
6 h after treatment with the high concentration and 6 h
after treatment with the low concentration of doxorubicin.
Among the agents examined in this study, vorinostat
resulted in the highest number of positive matches to
available independent datasets, suggesting that this agent
induces strong concerted changes in the expression of
genes involved in DNA methylation and one-carbon me-
tabolism that are specific to HDAC inhibitors. We found
multiple top matches to LINCS experiments at 6 and
24 h after treatment with 10,000 and 11,100 nM of vorino-
stat and/or after treatment with other HDAC inhibitors, tri-
chostatin A and ISOX, when we used L1000CDS2 searches
with lists of genes from 2 and 6 h after treatment with the
high concentration and 2, 6, and 24 h after treatment with
the low concentration of vorinostat. When L1000CDS2
searches utilized both gene lists in Table 1 and their
median log2 FC values after treatment with vorinostat,
a very large number of top matches from the LINCS
database was found that included HDAC inhibitors
vorinostat, trichostatin A, HDAC6 inhibitor ISOX, droxino-
stat (BRD-K11558771), belinostat (S1085), abexinostat
(THM-I-94; PCI-24781), and dacinostat (BRD-K56957086).
These strong matches were observed for both high and low
concentrations and all the three time points after treatment
with vorinostat in our dataset. They included the best hit
for vorinostat experiments for each of the L1000CDS2
search that used our results at 6 h after treatment with the
high and low concentrations and at 24 h after treatment
with the low concentration of vorinostat. LINCS Canvas
Browser (LCB) searches using genes in Table 1 involved in
response to vorinostat also returned multiple high-ranking
LINCS hits for vorinostat and trichostatin A. Among them,
vorinostat experiments were the best match for each LCB
search that used concerted gene lists from Table 1 at 6 h
after treatment with the high and low concentrations of the
agent and the second best hit for the gene list from 2 h
after treatment with the high concentration.
Because of the small number of candidate genes with
concerted expression response to paclitaxel (Table 1),
searches for paclitaxel could only be conducted for the
24-h time point. An LCB search using genes with concerted
response to the low concentration of paclitaxel returned ex-
periments involving 24 h after treatment with 10,000 nM of
docetaxel, an agent with a similar mechanism of action to
paclitaxel, among the top hits. In addition, even though our
gene lists were restricted to epigenetic components and
OCM genes, both L1000CDS2 and LCB searches using
genes with concerted response to high and low concentra-
tions of paclitaxel returned several antimitotic and micro-
tubule targeting agents including narciclasine, curcubitacin
I, and vincristine, suggesting a possibility of some simi-
lar transcriptional response among epigenetic factors
and OCM genes to these agents.
The searches of response to cisplatin could only be
performed for the gene lists corresponding to 6 and 24 h
after treatment with the high concentration of the agent
because of the very limited number of genes with con-
certed expression changes for other conditions (Table 1).
No LINCS experiments specific to cisplatin on other
platinum agents were returned by any of these searches.
This may suggest that, in contrast to other agents, the
concerted changes among genes involved in epigenetic
and OCM response to cisplatin that were identified in
our study may not be specific to platinum compounds,
and they may also occur in response to other classes of
cancer agents. In contrast, our searches of independent
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datasets and perturbation experiments indicate that
patterns of concerted changes in the expression of epi-
genetic and OCM genes in response to 5-azacytidine,
doxorubicin, vorinostat, and paclitaxel may be specific to
their classes of agents.
Statistical significance of concerted expression changes
Additional file 1: Table S2 provides estimates of whether
the number of genes with concerted regulation changes
among the 56 candidate genes examined in this study is
significantly greater than what would be expected for a
random set of 56 genes. Concerted changes in the
expression satisfied Bonferroni-adjusted threshold of
statistical significance at 24 h of treatment with both
high (p = 0.0001) and low (p < 0.0001) concentrations
of paclitaxel. For several other agents and condi-
tions, p values were below 0.05, but they did not
achieve Bonferroni-adjusted threshold for multiple
testing. These conditions include 6 h after treatment
with the low concentration of 5-azacytidine, 6 and
24 h after treatment with the low concentration of
doxorubicin, and 24 h after treatment with the high
and low concentrations of vorinostat. Statistical sig-
nificance of concerted changes after treatment with
paclitaxel is likely explained by the small numbers of
overall genome-wide concerted expression changes after
treatment with this agent, as opposed to much more wide-
spread concerted expression changes after treatment with
other agents examined in this study. For example, 5-
azacytidine and vorinostat lead to very strong and exten-
sive genome-wide transcriptional changes that include
concerted changes in the expression of many genes from
different cellular pathways. The focus of our study was
centered on components of one-carbon metabolism and
of epigenetic DNA methylation and demethylation ma-
chinery, some of which, including DNMT1, represent
direct biological targets of some of the agents that
were examined. A number of these individual components
of the epigenetic and the OCM pathways exhibited
concerted changes in response to treatment. Some
other genes in the genome, e.g., those involved in
DNA repair, cell cycle regulation, and cell death, also
had concerted expression changes in response to treat-
ment, resulting in the total numbers of epigenetic and
OCM components with concerted changes not being
significant for agents other than paclitaxel. The ab-
sence of statistical significance of the total numbers of
candidate genes with concerted changes is therefore
due to large numbers of additional genes with con-
certed changes of expression, and it does not contra-
dict the biological changes in the expression of
individual components of DNA methylation, demeth-
ylation, and the OCM pathways in response to
treatment.
Correlation of cancer cell sensitivity to drug treatment
with expression changes in genes involved in DNA
methylation, demethylation, and the OCM pathway
When NCI-60 cell lines were treated with 5-azacytidine
or vorinostat, the correlation between chemosensitivity,
measured as log(GI50), and expression changes of any of
the 56 candidate genes involved in DNA methylation,
demethylation, and the OCM pathway was weak (none
of the correlation tests reached significance, and in many
cases Pearson’s |r| < 0.4). In addition, none of the 91 poten-
tial methylation target genes had statistically significant cor-
relations with log(GI50) with after treatment with these
agents. The absence of correlation between gene expression
changes and chemosensitivity to 5-azacytidine is consistent
with an earlier report that 5-azacytidine induced global
genome-wide hypomethylation that prolonged survival of
patients with myeloid malignancies but did not correlate
with clinical prognosis or response to therapy [1]. In our
analysis, epigenetic components of DNA methylation ma-
chinery and the OCM pathway members demonstrated
considerable changes in their transcriptional response to
treatment with 5-azacytidine (Table 1; Figs. 1 and 2,
Additional file 2: Figures S1-S4); however, these
changes were only weakly correlated with chemosensitivity
(r < 0.4 for all 56 candidate genes listed in Table 1).
Table 2 provides the list of genes involved in DNA
methylation, demethylation, and the OCM pathway that
showed significant correlation of their expression changes
with chemosensitivity to doxorubicin, paclitaxel, or cis-
platin. All significant correlations were observed at 24 hours
after treatment. After treatment with doxorubicin, expres-
sion changes of FOLR2 and SMUG1 were significantly
negatively correlated with chemosensitivity. FOLR2, which
encodes folate receptor 2, was upregulated at 24 h after
treatment with the high concentration of doxorubicin,
which was inversely correlated with chemosensitivity
(Pearson’s r = −0.509, FDR adjusted p = 0.0366; Tables 1
and 2). This association is of interest because FOLR2 is
currently used as a target for folate-mediated delivery
of doxorubicin to cancer cells, and tumor cells with in-
creased expression of FOLR2 demonstrate enhanced
cytotoxicity when treated with doxorubicin delivered in
folate-dependent manner [100, 112]. For the dataset
used in this study, the NCI-60 cell lines were grown on
RPMI 1640 medium (Life Technologies, Inc.) that con-
tained 1 μg/ml of folic acid and was supplemented with
5 % fetal bovine serum, and therefore, the presence of
folate in the growth media may have contributed to
FOLR2-dependent chemosensitivity to doxorubicin de-
livery and treatment.
SMUG1 was upregulated at 24 h after treatment with
doxorubicin, and this change was negatively correlated
with chemosensitivity to the low concentration (r = −0.488,
FDR adjusted p = 0.0284; Tables 1 and 2). SMUG1 is a
Krushkal et al. Clinical Epigenetics  (2016) 8:73 Page 16 of 24
member of the uracil-DNA glycosylase superfamily,
which is involved in DNA repair and DNA demethyl-
ation [1, 6, 74]. The observed negative correlation be-
tween upregulation of SMUG1 and chemosensitivity
to doxorubicin is in agreement with the potential role
of this gene in the removal, via the BER pathway, of
DNA damage induced by doxorubicin (Additional file
1: Table S1) [94].
A significant correlation with chemosensitivity to pacli-
taxel was observed only for GART, which is involved in pur-
ine biosynthesis. It was downregulated at 24 h after
treatment, and changes in its expression were significantly
correlated with log(GI50) of the low concentration of pacli-
taxel (r = 0.462, FDR adjusted p = 0.0422; Tables 1 and 2).
Among the five cancer agents, the highest number of
significant correlations of gene expression changes with
chemosensitivity was observed at 24 h after treatment
with cisplatin, with stronger correlations observed for
the high concentration of that agent. As described above,
chemosensitivity to cisplatin was also correlated with
expression changes of multiple potential DNA methylation
target genes. Among the 56 candidate genes from
Table 1, significant correlations were observed for
GADD45A, MBD1, MTR, MTHFD1, and CTH (Table 2).
Components of DNA demethylation and DNA repair
machinery GADD45A and MBD1 were upregulated at
24 h after treatment, and their expression changes were
inversely correlated with chemosensitivity (for GADD45A,
r = −0.618, FDR adjusted p = 0.0011 for the high concen-
tration and r = −0.477, p = 0.0422 for the low concentra-
tion of cisplatin, and for MBD1, r = −0.570, p = 0.0046 for
the high concentration; Tables 1 and 2). The observed
negative correlation for MBD1 and GADD45A is in agree-
ment with their previously reported roles in chemoresis-
tance to cisplatin. Both genes participate in DNA repair
and DNA damage checkpoint response, and inhibition of
each gene has been reported to sensitize pancreatic and
colon cancer cells to cisplatin and to radiation treatment
[55, 113].
Expression changes of three OCM genes were also
correlated with chemosensitivity to cisplatin (Table 2) at
24 h after treatment. Among them was MTHFD1, ex-
pression changes for which did not satisfy the criteria
for a concerted pattern, but which demonstrated a sig-
nificant positive correlation with chemosensitivity to
the high concentration of cisplatin (r = 0.552, p =
0.0061). MTR was downregulated, which was signifi-
cantly correlated with chemosensitivity to the high
concentration (r = 0.564, p = 0.0046). CTH was upreg-
ulated after treatment with the high concentration of
the cisplatin (Table 1; Additional file 2: Figure S3D),
and the changes in its expression were significantly
inversely correlated with chemosensitivity (r = −0.531,
p = 0.0122 after treatment with the high concentration
and −0.504, p = 0.234 after treatment with the low
concentration; Table 2).
Conclusions
Our results suggest that despite a high level of genetic
and cancer type heterogeneity among different tumor
cell lines in the NCI-60 panel, multiple genes encoding
epigenetic factors and members of the OCM pathway
exhibited expression changes in the same direction
across most of the cell lines in response to several cancer
drugs analyzed in this study. Concerted changes in the ex-
pression of epigenetic and OCM pathways across different
cell lines were observed even for antitumor agents such as
paclitaxel and cisplatin that are not specifically targeting
epigenetic machinery or folate-dependent cellular pro-
cesses. Better understanding of epigenetic response and of
changes in the OCM pathway in response to treatment
may have implications for future design of drug combin-
ation therapies. Additional studies are needed to better
understand how these changes correlate with DNA methy-
lation status and functional activity of individual down-
stream target genes, which may affect chemosensitivity of
cancer cells to treatment.
Concerted changes in gene expression were observed
most frequently at 24 h after treatment with the high
concentrations of antitumor agents, but for some indi-
vidual genes, the peaks of their concerted changes were
observed at 2 or 6 h. These observations suggest that a
delay in administration of individual antitumor agents
and the order of their administration may be beneficial
when designing drug combination therapies. This may
allow for additional treatment benefits based on the time
needed for target genes to become upregulated or down-
regulated after administering the first agent, as compared
to simultaneously administering the agents included in a
combination. This observation, which is based on analysis
of gene expression changes, is in agreement with earlier
studies that suggested the benefits of time-staggered ap-
proach and the need to optimize the drug doses and times
of their administration in drug combination therapies
when eliciting apoptotic response or involvement of epi-
genetic machinery [114, 115]. Because the available data-
set for this study was restricted to 2, 6, and 24 h following
the drug treatment, further analyses may be needed to
examine the optimal time points (e.g., those between 6
and 24 h or extending beyond the 24-h period) that
would maximize the benefits of treatment using spe-
cific doses of individual antitumor agents. While the
observed expression changes occurred rapidly, it may
be possible that longer intervals exceeding 24 h may
provide the full benefit of transition from molecular
epigenetic changes to transcription, translation, and
post-transcriptional and post-translation modification
of target genes involved in cellular response.
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The commonality of expression response patterns of
individual molecular components across different histologic
cancer types is of interest and may have clinical utility. It
suggests that each cancer drug examined in this study in-
duces some uniform biological response across a variety of
cell lines, which involves specific epigenetic factors and re-
actions in the OCM pathway. The underlying molecular
mechanisms of uniform response could be exploited in
drug combination therapies that may target a variety of
different cancer types. Two agents with broad epigenetic
effects, 5-azacytidine and vorinostat, induced strong con-
certed changes in the expression of members of methyla-
tion machinery and members of the OCM pathway. Even
though concerted transcriptional changes induced by these
two drugs were only weakly correlated with chemosensitiv-
ity, this strong response is beginning to be successfully
exploited in combination therapy treatments that aim to in-
crease cytotoxicity or overcome chemoresistance to individ-
ual agents by downregulating or upregulating methylation
target genes or genetic components of the OCM pathway
[30, 65, 67, 115].
Treatment with doxorubicin led to concerted changes
in the expression of DNA methylation machinery and of
members of the OCM pathway, and chemosensitivity to
doxorubicin was inversely correlated with upregulation
of the folate receptor FOLR2 gene. This finding further
validates the ongoing efforts to increase the efficacy of
doxorubicin treatment using the folate delivery system
that targets this receptor [100, 112].
When the cell lines were treated with cisplatin, ex-
pression changes of several genes involved in DNA de-
methylation and repair and in the OCM pathway were
correlated with chemosensitivity, suggesting their
importance in response to treatment and in drug re-
sistance. We also observed the correlation of tran-
scriptional changes of a number of additional genes
with chemosensitivity to cisplatin. The complex mech-
anisms of regulation of cellular response to cisplatin
and the possible roles of DNA methylation, repair, and
one-carbon metabolism reactions in this response re-
quire further investigation and may provide additional
cues for increasing the effectiveness of treatment and
for overcoming tumor resistance to this agent.
A number of combination therapy studies and clinical
trials targeting epigenetic factors are currently underway
[1, 28, 65, 66, 115, 116]. The benefits of targeting OCM
pathway members in a drug combination therapy involving
an antifolate drug, in some cases combined with an epigen-
etic cancer drug, are also becoming apparent [67]. A deeper
understanding of molecular changes in epigenetic response
and regulation of folate metabolism is important for appro-
priate timing and more focused targeting of molecular
components of cancer cells. Changes in the expression of
some of the important genes analyzed in this study suggest
potential future directions of targeted epigenetic therapies
with a focus on specific genes. For example, while the DNA
methyltransferase DNMT1 gene was downregulated after
treatment with 5-azacytidine, doxorubicin, vorinostat, and
paclitaxel, the direction of expression changes of DNMT3A
and DNMT3B was specific to individual antitumor agents.
DNMT3A was downregulated by vorinostat, but it showed
a trend for upregulation in many cell lines after treatment
with doxorubicin. DNMT3B was downregulated by doxo-
rubicin, but it was upregulated after treatment with vorino-
stat. Further studies may examine whether combination
treatment therapies involving doxorubicin and vorinostat
may benefit from additional targeting of DNMT3A or
DNMT3B, by using either broad epigenetic agents or anti-
bodies specifically targeting these DNA methyltransferases.
Similarly, upregulation of TYMS and DHFR after treatment
with doxorubicin and cisplatin suggests a possibility that
targeting products of these genes in a drug combination
involving either of these drugs may provide additional cyto-
toxic benefits. Additional information in Table 1 that lists
changes among multiple epigenetic factors and members of
the OCM pathway in response to treatment may provide
further suggestions for expanding the repertoire of molecu-
lar targets in combination treatment regimens.
Methods
Gene expression analysis
We investigated time-dependent effects of several cancer
drugs on the expression of genes involved in DNA methy-
lation, demethylation, and folate-dependent one-carbon
metabolism pathways. For this purpose, we used longitu-
dinal gene expression information derived from time
course Affymetrix HG-U133A microarray expression ex-
periments that involved the NCI-60 cancer cell line panel.
These data were obtained from the TP Workbench of the
National Cancer Institute. The TP Workbench tool pro-
vides visual and analytic representation of gene expression
changes in the NCI-60 cancer cell lines treated with 15
anticancer drugs at 2, 6, and 24 h after treatment. Five of
these drugs (5-azacytidine, doxorubicin, vorinostat, pacli-
taxel, and cisplatin) for which the data were available were
selected for analysis in this study based on their reported
effects on DNA methylation and/or the role of epigenetic
factors in resistance to those agents. At each time point
(2, 6, and 24 h) after treatment and for each of the 15 anti-
tumor agents, expression levels were measured in all of
the 60 cell lines treated with high and low concentrations
of the drug and compared to time-matched control ex-
pression levels where cells were treated with vehicle only.
The TP Workbench contains the dataset with expression
measurements for 22,227 probe sets that were processed
using background subtraction of CEL files and array
normalization procedure using the robust multi-array
average (RMA) algorithm [117]. The output expression
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values for each probe set corresponding to different
probes within a single gene were combined from a sin-
gle microarray by averaging log2 values of probe mea-
surements, resulting in gene level-averaged output for
12,704 genes that were included in the Affymetrix U133A
microarrays. Averaging of probe measurements for each
gene was done separately and independently for each
microarray dataset (for each given time point, and separ-
ately for untreated cell lines, cell lines treated with low drug
concentration, and cell lines treated with a high drug con-
centration). The TP Workbench tool allows the users to
view the post-treatment expression change for each gene in
each individual cell line, presented as log2 of fold change of
expression values of that gene (we refer to this value as log2
FC). The value of log2 FC is presented as a difference be-
tween the log2 of the averaged gene expression value in a
cell line treated with a particular agent and the log2 of the
averaged expression value of that gene in the same cell line
that was treated only with vehicle and collected at time-
matched intervals (2, 6, or 24 h after treatment). The de-
tailed description of the data and tools in the Transcrip-
tional Pharmacology Workbench and of experimental
methodology that had been used to derive these data is pro-
vided by Monks et al. (Monks A, Zhao Y, Hose C, Fang J,
Polley E, Harris E, Wu X, Connelly J, Rapisarda A, Teicher
B, Simon R, Doroshow JH.:Transcriptional Pharmacology
Workbench: a powerful web tool to explore NCI60 time
course data on genome-wide response to treatment with
drugs, In preparation).
To monitor the concerted pattern of changes in each
experiment, we introduced a threshold on the number
of cell lines with discordant pattern of direction of
change in gene expression. We denoted changes in ex-
pression as either upregulated or downregulated for
those microarray experiments (specific to an antitumor
agent, its concentration, and post-treatment time) in
which the expression of nearly all NCI-60 cell lines
changed in the same direction, and no more than 15 cell
lines (N ≤ 15, i.e., no more than 25 % of the full dataset
of 60 cell lines) had a change in the opposite direction.
This filtering allowed us to identify the genes with the
strongest trends for concerted expression changes among
the cell lines. The probability that no more than 15 genes
would be expressed in the opposite direction at random
was computed based on the probability mass function of
the binomial distribution using the pbinom function of the
R environment, as the sum of p(N ≤ 15) + (1 − p(N ≤ 45)).
We used genome-wide expression data to estimate the
probability of any individual gene to be downregulated as
opposed to being upregulated, separately for each drug,
time point, and concentration. It was determined to be
close to 0.5 for all 30 experiments (the range between 0.476
and 0.525). Based on these estimates and the numbers of
cell lines with measured expression changes for each
experiment, the probability of no more than 15 cell lines to
be expressed in the opposite direction in a given experi-
ment at random was found to be low, ranging between
6.96 × 10−5 and 1.54 × 10−3 for individual agents, time
points, and drug concentrations.
Drug concentrations
Expression levels of candidate genes involved in DNA
methylation, demethylation, and one-carbon metabolism
pathways were examined in cell lines treated with five
antitumor agents, 5-azacytidine, doxorubicin, vorinostat,
paclitaxel, and cisplatin. For each of the drugs, the high
and low concentrations were chosen to approximate a
clinically achievable concentration and an in vitro active
concentration. They were, respectively, 5-azacytidine,
5000 and 1000 nM; doxorubicin, 1000 and 100 nM; vori-
nostat, 5000 and 1000 nM; paclitaxel, 100 and 10 nM;
and cisplatin, 15000 and 3000 nM. For each drug con-
centration at each time point (2, 6, and 24 h after treat-
ment), the TP Workbench output was provided as log2
FC of gene expression levels in each cell line treated
with that concentration of the drug relative to those in
the untreated cell line, measured at the same time point.
Selection of candidate genes involved in DNA methylation,
demethylation, and folate-mediated one-carbon metabolism
pathway
Fifty-six candidate genes (Table 1; Additional file 1: Table S1)
were selected for expression analysis based on their bio-
logical roles in methylation or demethylation of DNA or
their involvement in the folate-mediated one-carbon metab-
olism pathway based on information from biomedical litera-
ture [5, 6, 8, 9, 11–15, 17, 18, 24, 60, 74, 77–79, 84, 118–122]
and using information from the Kyoto Encyclopedia of
Genes and Genomes (KEGG) [123], GeneCards [124],
and the Online Mendelian Inheritance in Men (OMIM)
[125] databases. Additional information about interactions
of candidate genes with cancer drugs was obtained from
the Drug Gene Interaction database (DGIdb) [126] and
from the Pharmacogenomics Knowledgebase (PharmGKB)
[127].
Validation of concerted gene expression changes in other
datasets
To confirm concerted gene expression changes in other
datasets, we examined the gene signatures involved in
transcriptional response to the drug treatment by searching
the Molecular Signatures Database (MSigDB) v. 5.1 [72]
and the biomedical literature for relevant treatment condi-
tions. We also examined whether patterns of gene up- and
downregulation observed in our study could be confirmed
in independent expression datasets that included the cmap
build 2 [110] and the LINCS.
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The Connectivity Map provides data for gene expression
changes in cell lines at 6 h after treatment, measured using
the Affymetrix U133A expression microarrays. Available
concentrations in cmap exceed the high concentrations in
the TP Workbench, with the exception of one experiment
(instance) of the MCF7 cell line-treated paclitaxel at
100 nM. All other available concentrations in cmap were
5-azacytidine, 16,400 nM; doxorubicin, 6800 nM; vorino-
stat, 10,000 nM; and paclitaxel, 4600 nM, with no data
available for cisplatin. We used the lists of Affymetrix
U133A microarray probesets for genes satisfying the
criteria for concerted up- and downregulation at 6 h after
treatment with the high concentrations in our study
(Table 1), in order to analyze whether these groups of
genes were among the top cmap rankings based on the
degree of their expression changes, using online searches
and permutation analysis provided by the Connectivity
Map online interface [110].
The LINCS dataset utilizes expression measures for
thousands of treatment conditions for approximately
1000 genes and imputed expression values for approxi-
mately 22,000 remaining genes [128]. We searched
LINCS data using two search engines, L1000CDS2 and
the LCB, which employ different approaches for finding
similarities among gene sets representing each experi-
ment [128–130]. LCB provides a search engine of at
least 150,000 experimental conditions [128], whereas
L1000CDS2 contains data on 389,031 precomputed gene
signatures derived from LINCS data [130]. The lists of
up- and downregulated genes with concerted expression
changes (Table 1) for each agent, concentration, and
time point were used as input for LCB and L1000CDS2.
Additionally, we also used the L1000CDS2 search engine
using gene signatures derived from Table 1 in our study,
by providing the lists of genes with concerted regulation
and their gene-specific median log2 FC values computed
for each agent, treatment condition, and time point.
These searches were conducted for those conditions in
Table 1 that satisfied the search engine requirements for
the number of input genes (≥3 of both upregulated and
downregulated genes for a gene list or ≥5 genes for an
input signature used by L1000CDS2; ≥2 genes with the
same direction of concerted regulation for an input used
by LCB). The results of the searches were considered to
be among the top hits when they were returned in the
default lists of hits (≤50 best hits for both search engines).
Evaluation of statistical significance of the numbers of
genes with concerted expression changes
In order to evaluate the statistical significance of the
numbers of genes with concerted expression changes,
we employed resampling analysis for each drug concentra-
tion and each time point. We used repeated sampling with-
out replacement of 56 random genes from the 12,704 genes
for which quality-processed expression data from the
Affymetrix U133A expression microarray were available in
the TP Workbench dataset. For each round of replications,
we determined the number of genes satisfying the con-
dition of co-regulation (the number of cell lines with
expression in the opposite direction ≤15). For each agent,
concentration, and time point, the empirical p value was es-
timated by computing the proportion of occurrences, out
of 10,000 replications, when the number of co-regulated
genes in a random sample was equal to or exceeded that
for the 56 candidate genes in DNA methylation, demethyla-
tion, and OCM pathways for the same time point and con-
centration of the agent. The empirical p value threshold for
statistical significance was adjusted for the number of tests
(30 tests for 5 agents, 2 concentrations, and 3 time points)
according to the Bonferroni procedure, resulting in
adjusted threshold of 0.00167.
Hierarchical clustering and heatmap analysis of
expression response of potential gene targets of DNA
methylation and demethylation pathways
Epigenetic action of some cancer drugs can reactivate ex-
pression of tumor suppressor genes and induce changes in
the expression of genes involved in regulation of cell cycle,
DNA repair, metabolic processes, and biosynthesis of im-
portant cell compounds [1, 2, 32, 37, 53, 89]. DNA demeth-
ylation is one of the mechanisms that cause transcriptional
changes in response to cancer drug treatment [1, 53].
Additionally, epigenetic factors involved in DNA methyla-
tion and demethylation machinery contribute to the cyto-
toxic action of anticancer agents via the activation of the
apoptotic pathways [1, 32, 34, 53]. To examine the simul-
taneous effects of cancer drug treatment on the expression
of epigenetic factors and of their downstream targets,
along with genes involved in OCM pathway, we analyzed
the microarray data in the Transcriptional Pharmacology
Workbench, by simultaneously monitoring changes in the
expression of the 56 genes listed in Table 1 and 91 add-
itional genes. These additional genes play important roles
in cancer development and in cellular response to cancer
drug treatment, and modulation of their expression levels
in tumor cells prior to treatment and/or in response to
treatment by one or more agents analyzed in this study
have been suggested to involve components of epigenetic
machinery, based on either direct methylation measures
or indirect inference using gene expression information
[1–3, 32, 34, 37, 44, 45, 49, 53, 86, 89, 91]. This list of po-
tential DNA methylation and demethylation target genes
included BAK1, TP53 (p53), TP53TG1 (TP53AP1), RIPK2,
BCL2, CCNB1, CASP5, CASP6, BRCA1, BRCA2, PTEN
(p10), CDKN1A (p21), CDKN2A (p16), CDKN2B (p15),
CDKN1C (p57), DLC1, TERT, SMG1, GTSE1, CHAF1A,
RAD21, SMC3, SSRP1, HMGB2, CCNA2, RECQL, NEIL3,
SMC5,TIPIN, ASF1A, NBN, CHEK1, DYRK2, ZAK (AZK),
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POLA1 (POL1), POLB, SFPQ, PMS1, RAD50, KAT5
(HTATIP), DCLRE1C, FAN1 (MTMR15), CEBPG, FANCE,
FANCF, UVRAG, MLH3, ATXN3, SMC6, UPF1, GTF2H1,
NHEJ1, PPP1R15A (GADD34), FOXO3 (FOXO3A), APTX,
CCNO, TRIAP1, XPC, SFN (14-3-3σ), PTTG1, LIG1,
BCL3, PNKP, MYO6, DDB2, SESN1, DDIT3, BTG2,
MAP2K6, CD44, EDNRB (ETB), ESR1 (ER-α), FHIT,
GPC3, GSTP1, GATA1 (GATA), MLH1, CD82 (KAI1),
FABP3 (MDGI), ABCB1 (MDR1), MUC2, MYOD1, NME1
(NM23-H1), TP73 (p73), PAX6, RARB (RARβ2, or
NR1B2), RASSF1, TGFBR1, THBS1, TIMP3, and PLAU
(uPA). Changes in the expression of these genes were
analyzed using two-dimensional hierarchical clustering
and heat maps. This clustering tool is provided by the TP
Workbench, which utilizes the hclust function in the R
package heatmap.3, with a “complete linkage” option for
the agglomeration algorithm.
Analysis of correlation of gene expression changes with
chemosensitivity
For each drug concentration and each time point, we used
information from the TP Workbench and additional ana-
lyses using R environment v. 3.1.2 to examine Pearson’s
correlation between log2 FC of genes involved in DNA
methylation, DNA demethylation, and the OCM pathway
and their potential methylation targets and log(GI50)
values of the NCI-60 cell lines. Here, GI50 is a measure of
chemosensitivity of each NCI-60 cell line to an anticancer
agent, measured as a concentration (μM) producing 50 %
growth inhibition [31]. These GI50 values were generated
from a standard NCI-60 screening experiment [51] initi-
ated on the same day and with the same pot of cells that
were used to generate these expression profiling data.
Significance of correlation was evaluated according to the
Benjamini-Hochberg [131] correction procedure for false
discovery rate (FDR) using all p values from correlation
analyses of five antitumor agents, three time points after
treatment, and two concentrations of each drug. Genes
and conditions with corrected p < 0.05 were noted as
significantly associated with chemosensitivity or chemore-
sistance to treatment. All p values provided in this report
have been adjusted according to the FDR procedure.
Additional files
Additional file 1: Tables S1 and S2, and References for Table S1.
(PDF 262 kb)
Additional file 2: Figures S1-S17. (PDF 5851 kb)
Abbreviations
5-hmC, 5-hydroxymethylcytosine; AICDA (AID), activation-induced
cytidine deaminase; ALDH1L1, 10-formyl tetrahydrofolate dehydrogenase
(aldehyde dehydrogenase 1 family, member L1), cytosolic; ALDH2, aldehyde
dehydrogenase 2, mitochondrial; AMT, aminomethyltransferase; APOBEC1,
apolipoprotein B mRNA editing activity DNA deaminase 1; APOBEC2, apolipoprotein
B mRNA editing activity DNA deaminase 2; APOBEC3A, apolipoprotein B mRNA
editing activity DNA deaminase 3A; APOBEC3C, apolipoprotein B mRNA editing
activity DNA deaminase 3C; ATIC, 5-aminoimidazole-4-carboxamide
ribonucleotide formyltransferase; BER, base excision repair; BHMT,
betaine-homocysteine methyltransferase; CBS, cystathionine β-synthase;
CHFR, checkpoint with forkhead and ring finger domains; cmap, Connectivity
Map; CNS, central nervous system; CTH, cystathionase; DGIdb, Drug Gene
Interaction database; DHFR, dihydrofolate reductase; DLC1, deleted in liver
cancer; DNMT, DNA 5′ cytosine-methyltransferase; DNMT1, DNA methyltransferase
1; DNMT3A, DNA methyltransferase 3A; DNMT3B, DNA methyltransferase 3B;
DNMT3L, DNA methyltransferase 3-like protein; FC, fold change; FDH, 10-
formyltetrahydrofolate dehydrogenase; FDR, false discovery rate; FOLH1 (GCPII,
PSMA), folate hydrolase (glutamate carboxypeptidase II); FOLR1 (FRα), folate
receptor 1; FOLR2 (FRβ), folate receptor 2; FOLR3 (FRγ), folate receptor 3;
FTCD, glutamate formiminotransferase; GADD45A, growth arrest and DNA
damage 45 protein A; GART, phosphoribosylglycinamide formyltransferase;
Hcy, homocysteine; HDAC, histone deacetylase; IDH1, isocitrate dehydrogenase
1; IDH2, isocitrate dehydrogenase 2; KEGG, Kyoto Encyclopedia of Genes and
Genomes; L1000CDS2, LINCS L1000 Characteristic Direction Signature Search
Engine; LCB, LINCS Canvas Browser; LINCS, Library of Integrated Network-Based
Cellular Signatures; MAT1A, L-methionine S-adenosyltransferase I, alpha; MAT2A,
L-methionine S-adenosyltransferase II, alpha; MAT2B, L-methionine S-
adenosyltransferase II, beta; MBD1, methyl-CpG-binding domain protein 1;
MBD2, methyl-CpG-binding domain protein 2; MBD3, methyl-CpG-binding
domain protein 3; MBD4 (MED1), methyl-CpG-binding domain protein 4;
MeCP2, methyl-CpG-binding protein 2; MGMT, O(6)-methylguanine-DNA
methyltransferase; MTHFD1, methylenetetrahydrafolate dehydrogenase 1;
MTHFD2, methylenetetrahydrofolate dehydrogenase 2; MTHFD2L, methylenetetra-
hydrofolate dehydrogenase 2-like; MTHFR, 5,10-methylenetetrahydrafolate
reductase; MTHFS, methylenetetrahydrofolate synthase; MTR, methionine synthase;
MTRR, 5-methyltetrahydrafolate-homocysteine methyltransferase reductase; NNMT,
nicotinamide N-methyltransferase; OCM, folate-mediated one-carbon metabolism;
OMIM, Online Mendelian Inheritance in Men; PCNA, proliferating cell
nuclear antigen; PEMT, phosphatidylethanolamine-N-methyltransferase;
PharmGKB, Pharmacogenomics Knowledgebase; PON1, Paraoxonase 1; RMA,
robust multi-array average; ROS, reactive oxygen species; SAH, S-adeno-
sylhomocysteine; SAHA, suberoylanilide hydroxamic acid; SAM (AdoMet),
S-adenosylmethionine; SFN, stratifin; SHMT1, serine hydroxymethyl transferase 1;
SHMT2, serine hydroxymethyl transferase 2; SLC19A1 (RFC1), reduced folate
carrier; SMUG1, single-strand-selective monofunctional uracil-DNA glycosylase;
TCN2, transcobalamin II; TDG, thymine-DNA glycosylase; TERT (hTERT), human
telomerase reverse transcriptase; TET3, Tet methylcytosine dioxygenase 3
(ten-eleven translocation-3); THF, tetrahydrafolate; TP, Transcriptional
Pharmacology; TYMS (TS), thymidylate synthase; USP7 (HAUSP), Herpes
virus-associated ubiquitin specific protease.
Acknowledgements
We are grateful to the editor, Dr. Roderick Dashwood, and to the anonymous
reviewers of this manuscript for their helpful comments. We thank Drs. Eric Polley,
George Wright, Dmitriy Sonkin, Joanna Shih, Hossein Hamed, and Peter Szabo
(Biometric Research Program, National Cancer Institute) for helpful discussions.
Funding
This project has been funded in part with federal funds from the National
Cancer Institute, National Institutes of Health, under Contract No.
HHSN261200800001E. The content of this publication does not necessarily
reflect the views or policies of the Department of Health and Human Services,
nor does mention of trade names, commercial products, or organizations imply
endorsement by the U.S. Government. This research was supported [in part] by
the Developmental Therapeutics Program in the Division of Cancer Treatment
and Diagnosis of the National Cancer Institute.
Authors’ contributions
JK conceived and carried out the bioinformatic analysis of transcriptional
response measures and their correlation with drug sensitivity and drafted the
manuscript. YZ developed the Transcriptional Pharmacology Workbench tool
and participated in editing of the manuscript. AM oversaw the collection of
experimental data including cell culture growth, gene expression measures,
and drug response measures and participated in the interpretation of the
results and in editing of the manuscript. CH participated in experimental
data generation including cell culture growth, gene expression analysis, and
Krushkal et al. Clinical Epigenetics  (2016) 8:73 Page 21 of 24
collection of drug response measures. JHD participated in the design of the
experimental study, oversaw the completion and coordination of the
experimental and computational work, and participated in clinical
interpretation of the study results and in editing of the manuscript. RS oversaw
the design and computational development of the TP Workbench tool and the
statistical and computational analysis of the data, participated in the interpretation
of the study results, and edited the manuscript. All authors read and approved
the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Author details
1Biometric Research Program, Division of Cancer Treatment and Diagnosis,
National Cancer Institute, 9609 Medical Center Dr., Rockville, MD 20850, USA.
2Molecular Pharmacology Group, Leidos Biomedical Research, Inc., Frederick
National Laboratory for Cancer Research, Frederick, MD 21702, USA. 3Division
of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD
20892, USA.
Received: 26 January 2016 Accepted: 15 June 2016
References
1. Pleyer L, Greil R. Digging deep into “dirty” drugs—modulation of the
methylation machinery. Drug Metab Rev. 2015;47:252–79.
2. Baylin SB. DNA methylation and gene silencing in cancer. Nat Clin Pract
Oncol. 2005;2 Suppl 1:S4–11.
3. Herman JG, Merlo A, Mao L, Lapidus RG, Issa JP, Davidson NE, et al.
Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with
aberrant DNA methylation in all common human cancers. Cancer Res. 1995;
55:4525–30.
4. Das PM, Singal R. DNA methylation and cancer. J Clin Oncol. 2004;22:4632–42.
5. Plass C, Pfister SM, Lindroth AM, Bogatyrova O, Claus R, Lichter P. Mutations
in regulators of the epigenome and their connections to global chromatin
patterns in cancer. Nat Rev Genet. 2013;14:765–80.
6. Shen L, Song CX, He C, Zhang Y. Mechanism and function of oxidative
reversal of DNA and RNA methylation. Annu Rev Biochem. 2014;83:585–614.
7. Sedgwick B. Repairing DNA-methylation damage. Nat Rev Mol Cell Biol.
2004;5:148–57.
8. Niehrs C, Schafer A. Active DNA demethylation by Gadd45 and DNA repair.
Trends Cell Biol. 2012;22:220–7.
9. Shen H, Laird PW. Interplay between the cancer genome and epigenome.
Cell. 2013;153:38–55.
10. Baubec T, Ivanek R, Lienert F, Schubeler D. Methylation-dependent and
-independent genomic targeting principles of the MBD protein family. Cell.
2013;153:480–92.
11. Cartron PF, Nadaradjane A, Lepape F, Lalier L, Gardie B, Vallette FM.
Identification of TET1 partners that control its DNA-demethylating function.
Genes Cancer. 2013;4:235–41.
12. Prensner JR, Chinnaiyan AM. Metabolism unhinged: IDH mutations in cancer.
Nat Med. 2011;17:291–3.
13. Suetake I, Shinozaki F, Miyagawa J, Takeshima H, Tajima S. DNMT3L stimulates
the DNA methylation activity of Dnmt3a and Dnmt3b through a direct
interaction. J Biol Chem. 2004;279:27816–23.
14. Ulrich CM, Robien K, McLeod HL. Cancer pharmacogenetics: polymorphisms,
pathways and beyond. Nat Rev Cancer. 2003;3:912–20.
15. Nazki FH, Sameer AS, Ganaie BA. Folate: metabolism, genes, polymorphisms
and the associated diseases. Gene. 2014;533:11–20.
16. Kim YI. Nutritional epigenetics: impact of folate deficiency on DNA methylation
and colon cancer susceptibility. J Nutr. 2005;135:2703–9.
17. Stover PJ. Polymorphisms in 1-carbon metabolism, epigenetics and folate-related
pathologies. J Nutrigenet Nutrigenomics. 2011;4:293–305.
18. Fox JT, Stover PJ. Folate-mediated one-carbon metabolism. Vitam Horm.
2008;79:1–44.
19. Kelemen LE. The role of folate receptor alpha in cancer development,
progression and treatment: cause, consequence or innocent bystander?
Int J Cancer. 2006;119:243–50.
20. Andreassi MG, Botto N, Cocci F, Battaglia D, Antonioli E, Masetti S, et al.
Methylenetetrahydrofolate reductase gene C677T polymorphism,
homocysteine, vitamin B12, and DNA damage in coronary artery disease.
Hum Genet. 2003;112:171–7.
21. Figueiredo JC, Levine AJ, Crott JW, Baurley J, Haile RW. Folate-genetics and
colorectal neoplasia: what we know and need to know next. Mol Nutr Food
Res. 2013;57:607–27.
22. Lightfoot TJ, Johnston WT, Painter D, Simpson J, Roman E, Skibola CF, et al.
Genetic variation in the folate metabolic pathway and risk of childhood
leukemia. Blood. 2010;115:3923–9.
23. Zhang H, Liu C, Han YC, Ma Z, Zhang H, Ma Y, et al. Genetic variations in the
one-carbon metabolism pathway genes and susceptibility to hepatocellular
carcinoma risk: a case-control study. Tumour Biol. 2015;36:997–1002.
24. Vazquez A, Tedeschi PM, Bertino JR. Overexpression of the mitochondrial
folate and glycine-serine pathway: a new determinant of methotrexate
selectivity in tumors. Cancer Res. 2013;73:478–82.
25. Martinelli M, Scapoli L, Mattei G, Ugolini G, Montroni I, Zattoni D, et al.
A candidate gene study of one-carbon metabolism pathway genes and
colorectal cancer risk. Br J Nutr. 2013;109:984–9.
26. Yu W, Jin C, Lou X, Han X, Li L, He Y, et al. Global analysis of DNA methylation
by methyl-capture sequencing reveals epigenetic control of cisplatin resistance
in ovarian cancer cell. PLoS One. 2011;6:e29450.
27. Hagner N, Joerger M. Cancer chemotherapy: targeting folic acid synthesis.
Cancer Manag Res. 2010;2:293–301.
28. Jakopovic M, Thomas A, Balasubramaniam S, Schrump D, Giaccone G, Bates
SE. Targeting the epigenome in lung cancer: expanding approaches to
epigenetic therapy. Front Oncol. 2013;3:261.
29. Matherly LH, Wilson MR, Hou Z. The major facilitative folate transporters
solute carrier 19A1 and solute carrier 46A1: biology and role in antifolate
chemotherapy of cancer. Drug Metab Dispos. 2014;42:632–49.
30. Fahy J, Jeltsch A, Arimondo PB. DNA methyltransferase inhibitors in cancer:
a chemical and therapeutic patent overview and selected clinical studies.
Expert Opin Ther Pat. 2012;22:1427–42.
31. Holbeck SL, Collins JM, Doroshow JH. Analysis of Food and Drug
Administration-approved anticancer agents in the NCI60 panel of human
tumor cell lines. Mol Cancer Ther. 2010;9:1451–60.
32. Schneider-Stock R, Diab-Assef M, Rohrbeck A, Foltzer-Jourdainne C, Boltze C,
Hartig R, et al. 5-Aza-cytidine is a potent inhibitor of DNA methyltransferase
3a and induces apoptosis in HCT-116 colon cancer cells via Gadd45- and
p53-dependent mechanisms. J Pharmacol Exp Ther. 2005;312:525–36.
33. Patel AG, Kaufmann SH. How does doxorubicin work? Elife. 2012;1. e00387.
34. Yokochi T, Robertson KD. Doxorubicin inhibits DNMT1, resulting in conditional
apoptosis. Mol Pharmacol. 2004;66:1415–20.
35. Alakhova DY, Zhao Y, Li S, Kabanov AV. Effect of doxorubicin/pluronic
SP1049C on tumorigenicity, aggressiveness, DNA methylation and stem cell
markers in murine leukemia. PLoS One. 2013;8:e72238.
36. Li CT, Hsiao YM, Wu TC, Lin YW, Yeh KT, Ko JL. Vorinostat, SAHA,
represses telomerase activity via epigenetic regulation of telomerase
reverse transcriptase in non-small cell lung cancer cells. J Cell Biochem.
2011;112:3044–53.
37. Lee J, R SH. Cancer epigenetics: mechanisms and crosstalk of a HDAC
inhibitor, vorinostat. Chemotherapy (Los Angel). 2013;2:14934. doi: 10.4172/
2167-7700.1000111.
38. Zhou X, Yang XY, Popescu NC. Preclinical evaluation of combined
antineoplastic effect of DLC1 tumor suppressor protein and
suberoylanilide hydroxamic acid on prostate cancer cells. Biochem
Biophys Res Commun. 2012;420:325–30.
39. Fahrer J, Kaina B. O6-methylguanine-DNA methyltransferase in the defense
against N-nitroso compounds and colorectal cancer. Carcinogenesis. 2013;
34:2435–42.
40. Brown R, Curry E, Magnani L, Wilhelm-Benartzi CS, Borley J. Poised epigenetic
states and acquired drug resistance in cancer. Nat Rev Cancer. 2014;14:747–53.
41. Heyn H, Esteller M. DNA methylation profiling in the clinic: applications and
challenges. Nat Rev Genet. 2012;13:679–92.
42. Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance.
Oncogene. 2003;22:7265–79.
43. Shen DW, Pouliot LM, Hall MD, Gottesman MM. Cisplatin resistance: a cellular
self-defense mechanism resulting from multiple epigenetic and genetic
changes. Pharmacol Rev. 2012;64:706–21.
44. Zeller C, Dai W, Steele NL, Siddiq A, Walley AJ, Wilhelm-Benartzi CS, et al.
Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian
cancer identified by methylome and expression profiling. Oncogene. 2012;31:
4567–76.
Krushkal et al. Clinical Epigenetics  (2016) 8:73 Page 22 of 24
45. Zhang YW, Zheng Y, Wang JZ, Lu XX, Wang Z, Chen LB, et al. Integrated
analysis of DNA methylation and mRNA expression profiling reveals
candidate genes associated with cisplatin resistance in non-small cell lung
cancer. Epigenetics. 2014;9:896–909.
46. Rosell R, Taron M, Massuti B, Mederos N, Magri I, Santarpia M, et al.
Predicting response to chemotherapy with early-stage lung cancer.
Cancer J. 2011;17:49–56.
47. de Weger VA, Beijnen JH, Schellens JH. Cellular and clinical pharmacology
of the taxanes docetaxel and paclitaxel—a review. Anticancer Drugs. 2014;
25:488–94.
48. Das GC, Holiday D, Gallardo R, Haas C. Taxol-induced cell cycle arrest
and apoptosis: dose-response relationship in lung cancer cells of
different wild-type p53 status and under isogenic condition. Cancer
Lett. 2001;165:147–53.
49. Flanagan JM, Wilhelm-Benartzi CS, Metcalf M, Kaye SB, Brown R. Association of
somatic DNA methylation variability with progression-free survival and toxicity
in ovarian cancer patients. Ann Oncol. 2013;24:2813–8.
50. Yun T, Liu Y, Gao D, Linghu E, Brock MV, Yin D, et al. Methylation of CHFR
sensitizes esophageal squamous cell cancer to docetaxel and paclitaxel.
Genes Cancer. 2015;6:38–48.
51. Monks A, Scudiero D, Skehan P, Shoemaker R, Paull K, Vistica D, et al.
Feasibility of a high-flux anticancer drug screen using a diverse panel of
cultured human tumor cell lines. J Natl Cancer Inst. 1991;83:757–66.
52. Murphy SK. Targeting the epigenome in ovarian cancer. Future Oncol. 2012;
8:151–64.
53. Nguyen AN, Hollenbach PW, Richard N, Luna-Moran A, Brady H, Heise C,
et al. Azacitidine and decitabine have different mechanisms of action in
non-small cell lung cancer cell lines. Lung Cancer. 2010;1:119–40.
54. Barreto G, Schafer A, Marhold J, Stach D, Swaminathan SK, Handa V, et al.
Gadd45a promotes epigenetic gene activation by repair-mediated DNA
demethylation. Nature. 2007;445:671–5.
55. Xu J, Zhu W, Xu W, Cui X, Chen L, Ji S, et al. Silencing of MBD1 reverses
pancreatic cancer therapy resistance through inhibition of DNA damage
repair. Int J Oncol. 2013;42:2046–52.
56. Prokhortchouk E, Hendrich B. Methyl-CpG binding proteins and cancer: are
MeCpGs more important than MBDs? Oncogene. 2002;21:5394–9.
57. Cheishvili D, Chik F, Li CC, Bhattacharya B, Suderman M, Arakelian A, et al.
Synergistic effects of combined DNA methyltransferase inhibition and
MBD2 depletion on breast cancer cells; MBD2 depletion blocks 5-aza-2′-
deoxycytidine-triggered invasiveness. Carcinogenesis. 2014;35:2436–46.
58. Zhao R, Goldman ID. Folate and thiamine transporters mediated by facilitative
carriers (SLC19A1-3 and SLC46A1) and folate receptors. Mol Aspects Med.
2013;34:373–85.
59. Hou Z, Matherly LH. Biology of the major facilitative folate transporters
SLC19A1 and SLC46A1. Curr Top Membr. 2014;73:175–204.
60. Murray B, Antonyuk SV, Marina A, Van Liempd SM, Lu SC, Mato JM,
et al. Structure and function study of the complex that synthesizes
S-adenosylmethionine. IUCrJ. 2014;1:240–9.
61. Wang YC, Chiang EP. Low-dose methotrexate inhibits methionine
S-adenosyltransferase in vitro and in vivo. Mol Med. 2012;18:423–32.
62. Iacobazzi V, Castegna A, Infantino V, Andria G. Mitochondrial DNA
methylation as a next-generation biomarker and diagnostic tool. Mol Genet
Metab. 2013;110:25–34.
63. Tehlivets O, Malanovic N, Visram M, Pavkov-Keller T, Keller W. S-adenosyl-L-
homocysteine hydrolase and methylation disorders: yeast as a model
system. Biochim Biophys Acta. 1832;2013:204–15.
64. Blom HJ, Smulders Y. Overview of homocysteine and folate metabolism.
With special references to cardiovascular disease and neural tube defects.
J Inherit Metab Dis. 2011;34:75–81.
65. Bhatla T, Wang J, Morrison DJ, Raetz EA, Burke MJ, Brown P, et al. Epigenetic
reprogramming reverses the relapse-specific gene expression signature and
restores chemosensitivity in childhood B-lymphoblastic leukemia. Blood.
2012;119:5201–10.
66. LaBonte MJ, Wilson PM, Fazzone W, Groshen S, Lenz HJ, Ladner RD.
DNA microarray profiling of genes differentially regulated by the
histone deacetylase inhibitors vorinostat and LBH589 in colon cancer
cell lines. BMC Med Genomics. 2009;2:67.
67. Di Gennaro E, Bruzzese F, Pepe S, Leone A, Delrio P, Subbarayan PR, et al.
Modulation of thymidilate synthase and p53 expression by HDAC inhibitor
vorinostat resulted in synergistic antitumor effect in combination with 5FU
or raltitrexed. Cancer Biol Ther. 2009;8:782–91.
68. Lee SJ, Hwang SO, Noh EJ, Kim DU, Nam M, Kim JH, et al. Transactivation of
bad by vorinostat-induced acetylated p53 enhances doxorubicin-induced
cytotoxicity in cervical cancer cells. Exp Mol Med. 2014;46:e76.
69. Ulanovskaya OA, Zuhl AM, Cravatt BF. NNMT promotes epigenetic remodeling in
cancer by creating a metabolic methylation sink. Nat Chem Biol. 2013;9:300–6.
70. Shlomi T, Rabinowitz JD. Metabolism: cancer mistunes methylation. Nat
Chem Biol. 2013;9:293–4.
71. Ghoshal K, Datta J, Majumder S, Bai S, Kutay H, Motiwala T, et al. 5-Aza-
deoxycytidine induces selective degradation of DNA methyltransferase 1 by a
proteasomal pathway that requires the KEN box, bromo-adjacent homology
domain, and nuclear localization signal. Mol Cell Biol. 2005;25:4727–41.
72. Liberzon A, Subramanian A, Pinchback R, Thorvaldsdottir H, Tamayo P,
Mesirov JP. Molecular signatures database (MSigDB) 3.0. Bioinformatics.
2011;27:1739–40. MSigDB: Molecular Signatures Database [database on the
Internet]. Available from: http://software.broadinstitute.org/gsea/msigdb/
index.jsp. Accessed: 18 Apr 2016.
73. Wang W, Huper G, Guo Y, Murphy SK, Olson Jr JA, Marks JR. Analysis of
methylation-sensitive transcriptome identifies GADD45a as a frequently
methylated gene in breast cancer. Oncogene. 2005;24:2705–14.
74. Franchini DM, Petersen-Mahrt SK. AID and APOBEC deaminases: balancing
DNA damage in epigenetics and immunity. Epigenomics. 2014;6:427–43.
75. Bronner C. Control of DNMT1 abundance in epigenetic inheritance by
acetylation, ubiquitylation, and the histone code. Sci Signal. 2011;4:pe3.
76. Varol N, Konac E, Bilen CY. Does Wnt/beta-catenin pathway contribute to
the stability of DNMT1 expression in urological cancer cell lines? Exp Biol
Med (Maywood). 2014.
77. Ji Y, Nordgren KK, Chai Y, Hebbring SJ, Jenkins GD, Abo RP, et al. Human
liver methionine cycle: MAT1A and GNMT gene resequencing, functional
genomics, and hepatic genotype-phenotype correlation. Drug Metab
Dispos. 2012;40:1984–92.
78. Lee MS, Bonner JR, Bernard DJ, Sanchez EL, Sause ET, Prentice RR, et al.
Disruption of the folate pathway in zebrafish causes developmental defects.
BMC Dev Biol. 2012;12:12.
79. Hazra A, Wu K, Kraft P, Fuchs CS, Giovannucci EL, Hunter DJ. Twenty-four
non-synonymous polymorphisms in the one-carbon metabolic pathway
and risk of colorectal adenoma in the Nurses’ Health Study. Carcinogenesis.
2007;28:1510–9.
80. Lau DT, Hesson LB, Norris MD, Marshall GM, Haber M, Ashton LJ. Prognostic
significance of promoter DNA methylation in patients with childhood
neuroblastoma. Clin Cancer Res. 2012;18:5690–700.
81. Stewart DJ, Nunez MI, Jelinek J, Hong D, Gupta S, Issa JP, et al.
Decitabine impact on the endocytosis regulator RhoA, the folate
carriers RFC1 and FOLR1, and the glucose transporter GLUT4 in human
tumors. Clin Epigenetics. 2014;6:2.
82. Cong X, Lu C, Huang X, Yang D, Cui X, Cai J, et al. Increased expression of
glycinamide ribonucleotide transformylase is associated with a poor
prognosis in hepatocellular carcinoma, and it promotes liver cancer cell
proliferation. Hum Pathol. 2014;45:1370–8.
83. Liu X, Ding Z, Liu Y, Zhang J, Liu F, Wang X, et al. Glycinamide
ribonucleotide formyl transferase is frequently overexpressed in glioma
and critically regulates the proliferation of glioma cells. Pathol Res Pract.
2014;210:256–63.
84. Shin M, Bryant JD, Momb J, Appling DR. Mitochondrial MTHFD2L is a
dual redox cofactor-specific methylenetetrahydrofolate dehydrogenase/
methenyltetrahydrofolate cyclohydrolase expressed in both adult and
embryonic tissues. J Biol Chem. 2014;289:15507–17.
85. Zhu WG, Hileman T, Ke Y, Wang P, Lu S, Duan W, et al. 5-aza-2′-
deoxycytidine activates the p53/p21Waf1/Cip1 pathway to inhibit cell
proliferation. J Biol Chem. 2004;279:15161–6.
86. Christman JK. 5-Azacytidine and 5-aza-2′-deoxycytidine as inhibitors of DNA
methylation: mechanistic studies and their implications for cancer therapy.
Oncogene. 2002;21:5483–95.
87. Arai M, Yokosuka O, Hirasawa Y, Fukai K, Chiba T, Imazeki F, et al. Sequential
gene expression changes in cancer cell lines after treatment with the
demethylation agent 5-aza-2′-deoxycytidine. Cancer. 2006;106:2514–25.
88. Mossman D, Kim KT, Scott RJ. Demethylation by 5-aza-2′-deoxycytidine in
colorectal cancer cells targets genomic DNA whilst promoter CpG island
methylation persists. BMC Cancer. 2010;10:366.
89. Hossain MZ, Healey MA, Lee C, Poh W, Yerram SR, Patel K, et al. DNA-intercalators
causing rapid re-expression of methylated and silenced genes in cancer cells.
Oncotarget. 2013;4:298–309.
Krushkal et al. Clinical Epigenetics  (2016) 8:73 Page 23 of 24
90. Song D, Ni J, Xie H, Ding M, Wang J. DNA demethylation in the PTEN gene
promoter induced by 5-azacytidine activates PTEN expression in the MG-63
human osteosarcoma cell line. Exp Ther Med. 2014;7:1071–6.
91. Qu Y, Dang S, Hou P. Gene methylation in gastric cancer. Clin Chim Acta.
2013;424:53–65.
92. Li LC, Okino ST, Dahiya R. DNA methylation in prostate cancer. Biochim
Biophys Acta. 1704;2004:87–102.
93. Liu L, Vo A, McKeehan WL. Specificity of the methylation-suppressed A isoform
of candidate tumor suppressor RASSF1 for microtubule hyperstabilization is
determined by cell death inducer C19ORF5. Cancer Res. 2005;65:1830–8.
94. Mohan V, Madhusudan S. DNA base excision repair: evolving biomarkers for
personalized therapies in cancer. In: Chen C, editor. Evolving drug targets in
DNA base excision repair for cancer therapy, InTech. 2013. p. 529–58.
95. Teng YW, Mehedint MG, Garrow TA, Zeisel SH. Deletion of betaine-
homocysteine S-methyltransferase in mice perturbs choline and 1-carbon
metabolism, resulting in fatty liver and hepatocellular carcinomas. J Biol
Chem. 2011;286:36258–67.
96. Li Q, Mao L, Wang R, Zhu L, Xue L. Overexpression of S-adenosylhomocysteine
hydrolase (SAHH) in esophageal squamous cell carcinoma (ESCC) cell lines:
effects on apoptosis, migration and adhesion of cells. Mol Biol Rep. 2014;41:
2409–17.
97. Otani T, Iwasaki M, Hanaoka T, Kobayashi M, Ishihara J, Natsukawa S, et al.
Folate, vitamin B6, vitamin B12, and vitamin B2 intake, genetic polymorphisms of
related enzymes, and risk of colorectal cancer in a hospital-based case-control
study in Japan. Nutr Cancer. 2005;53:42–50.
98. Graessmann M, Berg B, Fuchs B, Klein A, Graessmann A. Chemotherapy
resistance of mouse WAP-SVT/t breast cancer cells is mediated by
osteopontin, inhibiting apoptosis downstream of caspase-3. Oncogene.
2007;26:2840–50.
99. Oleinik NV, Krupenko NI, Krupenko SA. Epigenetic silencing of ALDH1L1, a
metabolic regulator of cellular proliferation, in cancers. Genes Cancer. 2011;
2:130–9.
100. Clarhaut J, Fraineau S, Guilhot J, Peraudeau E, Tranoy-Opalinski I, Thomas
M, et al. A galactosidase-responsive doxorubicin-folate conjugate for
selective targeting of acute myelogenous leukemia blasts. Leuk Res. 2013;
37:948–55.
101. De Luca P, Vazquez ES, Moiola CP, Zalazar F, Cotignola J, Gueron G, et al.
BRCA1 loss induces GADD153-mediated doxorubicin resistance in prostate
cancer. Mol Cancer Res. 2011;9:1078–90.
102. Meiyanto E, Fitriasari A, Hermawan A, Junedi S, Susidarti R. The improvement
of doxorubicin activity on breast cancer cell lines by tangeretin through cell
cycle modulation. Orient Pharm Exp Med. 2011;11:183–90.
103. Petruccelli LA, Dupere-Richer D, Pettersson F, Retrouvey H, Skoulikas S, Miller
Jr WH. Vorinostat induces reactive oxygen species and DNA damage in
acute myeloid leukemia cells. PLoS One. 2011;6:e20987.
104. Lanzi C, Cassinelli G, Cuccuru G, Supino R, Zuco V, Ferlini C, et al. Cell cycle
checkpoint efficiency and cellular response to paclitaxel in prostate cancer
cells. Prostate. 2001;48:254–64.
105. Kerley-Hamilton JS, Pike AM, Li N, DiRenzo J, Spinella MJ. A p53-dominant
transcriptional response to cisplatin in testicular germ cell tumor-derived
human embryonal carcinoma. Oncogene. 2005;24:6090–100.
106. Li J, Wood 3rd WH, Becker KG, Weeraratna AT, Morin PJ. Gene expression
response to cisplatin treatment in drug-sensitive and drug-resistant ovarian
cancer cells. Oncogene. 2007;26:2860–72.
107. D’Atri S, Graziani G, Lacal PM, Nistico V, Gilberti S, Faraoni I, et al.
Attenuation of O(6)-methylguanine-DNA methyltransferase activity and
mRNA levels by cisplatin and temozolomide in jurkat cells. J Pharmacol
Exp Ther. 2000;294:664–71.
108. Adusumilli PS, Chan MK, Chun YS, Hezel M, Chou TC, Rusch VW, et al.
Cisplatin-induced GADD34 upregulation potentiates oncolytic viral therapy
in the treatment of malignant pleural mesothelioma. Cancer Biol Ther. 2006;
5:48–53.
109. Fishel ML, Rabik CA, Bleibel WK, Li X, Moschel RC, Dolan ME. Role of GADD34
in modulation of cisplatin cytotoxicity. Biochem Pharmacol. 2006;71:239–47.
110. Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ, et al. The
Connectivity Map: using gene-expression signatures to connect small
molecules, genes, and disease. Science. 2006;313:1929–35. Available from:
https://www.broadinstitute.org/cmap/. Accessed: 18 Apr 2016.
111. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines:
molecular advances and pharmacologic developments in antitumor activity
and cardiotoxicity. Pharmacol Rev. 2004;56:185–229.
112. Li H, Lu Y, Piao L, Wu J, Liu S, Marcucci G, et al. Targeting human clonogenic
acute myelogenous leukemia cells via folate conjugated liposomes combined
with receptor modulation by all-trans retinoic acid. Int J Pharm. 2010;402:57–63.
113. Moreira MP, Silva LM, Martins WK. The role of GADD45A in resistance to
oxidative stress-mediated cell death in human colon tumor cell lines.
Applied Cancer Research. 2009;29:179–84.
114. Lee MJ, Ye AS, Gardino AK, Heijink AM, Sorger PK, MacBeath G, et al.
Sequential application of anticancer drugs enhances cell death by rewiring
apoptotic signaling networks. Cell. 2012;149:780–94.
115. Azad N, Zahnow CA, Rudin CM, Baylin SB. The future of epigenetic therapy in
solid tumours—lessons from the past. Nat Rev Clin Oncol. 2013;10:256–66.
116. Fuller M, Klein M, Schmidt E, Rohde C, Gollner S, Schulze I, et al. 5-azacytidine
enhances efficacy of multiple chemotherapy drugs in AML and lung cancer
with modulation of CpG methylation. Int J Oncol. 2015;46:1192–204.
117. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, et al.
Exploration, normalization, and summaries of high density oligonucleotide
array probe level data. Biostatistics. 2003;4:249–64.
118. Watkins D, Rosenblatt DS. Update and new concepts in vitamin responsive
disorders of folate transport and metabolism. J Inherit Metab Dis. 2012;35:665–70.
119. Fiorito G, Guarrera S, Valle C, Ricceri F, Russo A, Grioni S, et al. B-vitamins
intake, DNA-methylation of one carbon metabolism and homocysteine
pathway genes and myocardial infarction risk: the EPICOR study. Nutr
Metab Cardiovasc Dis. 2014;24:483–8.
120. Metayer C, Scelo G, Chokkalingam AP, Barcellos LF, Aldrich MC, Chang JS,
et al. Genetic variants in the folate pathway and risk of childhood acute
lymphoblastic leukemia. Cancer Causes Control. 2011;22:1243–58.
121. Cheray M, Pacaud R, Nadaradjane A, Vallette FM, Cartron PF. Specific
inhibition of one DNMT1-including complex influences tumor initiation and
progression. Clin Epigenetics. 2013;5:9.
122. Zhang J, Gao Q, Li P, Liu X, Jia Y, Wu W, et al. S phase-dependent interaction
with DNMT1 dictates the role of UHRF1 but not UHRF2 in DNA methylation
maintenance. Cell Res. 2011;21:1723–39.
123. Kanehisa M, Goto S. KEGG: Kyoto Encyclopedia of Genes and Genomes.
Nucleic Acids Res. 2000;28(1):27–30. KEGG: Kyoto Encyclopedia of Genes
and Genomes [database on the Internet]. Available from: http://www.
genome.jp/kegg/kegg1.html. Accessed: 22 Jun 2015.
124. Stelzer G, Dalah I, Stein TI, Satanower Y, Rosen N, Nativ N, et al. In-silico
human genomics with GeneCards. Hum Genomics. 2011;5(6):709–17.
GeneCards®: The Human Gene Database [database on the Internet].
Available from: http://www.genecards.org/. Accessed: 3 Nov 2014.
125. OMIM®: Online Mendelian Inheritance in Man®. An Online Catalog of Human
Genes and Genetic Disorders. 2015. Available from: http://omim.org. Accessed:
27 Feb 2015
126. Griffith M, Griffith OL, Coffman AC, Weible JV, McMichael JF, Spies NC, et al.
DGIdb: mining the druggable genome. Nat Methods. 2013;10(12):1209–10.
DGIdb: The Drug Gene Interaction Database [database on the Internet].
Available from: http://dgidb.genome.wustl.edu. Accessed: 3 Nov 2014.
127. Whirl-Carrillo M, McDonagh EM, Hebert JM, Gong L, Sangkuhl K, Thorn CF,
et al. Pharmacogenomics knowledge for personalized medicine. Clin
Pharmacol Ther. 2012;92(4):414–7. PharmGKB: The Pharmacogenomics
Knowledgebase [database on the Internet]. Available from: https://www.
pharmgkb.org. Accessed: 3 Nov 2014.
128. Duan Q, Flynn C, Niepel M, Hafner M, Muhlich JL, Fernandez NF, et al. LINCS
Canvas Browser: interactive web app to query, browse and interrogate LINCS
L1000 gene expression signatures. Nucleic Acids Res. 2014;42:W449–60.
Available from: http://www.maayanlab.net/LINCS/LCB. Accessed: 27 Apr 2016.
129. Clark NR, Hu KS, Feldmann AS, Kou Y, Chen EY, Duan Q, et al. The characteristic
direction: a geometrical approach to identify differentially expressed genes.
BMC Bioinformatics. 2014;15:79.
130. Ma’ayan A, Duan Q. L1000CDS2: LINCS L1000 Characteristic Direction Signature
Search Engine. 2016. Available from: http://amp.pharm.mssm.edu/L1000CDS2/.
Accessed: 27 Apr 2016.
131. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and
powerful approach to multiple testing. J R Statist Soc. 1995;B.57:289–300.
Krushkal et al. Clinical Epigenetics  (2016) 8:73 Page 24 of 24
